var title_f30_29_31184="Two finger technique";
var content_f30_29_31184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Chest compression for infant resuscitation: Two finger technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 528px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIQAcQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqC8vLayhaa8uIbeJeryuFA/E1wPiL4q6TY7otIR9SuB3T5Y/8Avo9fwpNpbjUXLY9FpjOBXgd78UPFF3Iwt47W0jPTam5v1rAvvF/iu4crJq8yD/YAX+VT7SJqqEz6Wa4A71E14g6mvl19a18vufVr3PqJDU8Pi7xJbEAalK6j/nphv50vaxD2Ej6bF6nrUqXSHuK+cbf4i67GR5qW8wH+yVP862bL4nT5AuLLaO5WT/61UpxfUl0pLoe9LKp708EGvNND8bW19tCuUc/wtXXWOrpLj5hV2MzdoqGGdZBkEVMDSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEdlRSzEBQMkntXlXjr4nRwPJp/h7M1yCVecfdX6VW+M/jN4HXQtLl2yvzO6nkf7NedaRp+1MAZY/eJ7mspztojejS5tWGb7V7kT6lPLO3q5zj6Vrw6dGsfyIM1ctbHYACOa27OxOzkdawd2d0bRVkcbPaOHOBVZrR2f7td/JpWRnbkVWOlKWwRTsQ2cRcWZVRlfxFV1sGcHADCu/n0Y7ML/Ks1tKkifOMUCuca9gw6D86iNoQDgc12kmmsVztrMvLTyTnHWkXY5YxTQPvt3ZHHOM11/hfxdKGWK8fDDgtWPcxBl4rHuLdoyWUkEcg1pCbiZVKSlsfQmia0JVX5xXVW10HUc189eCNffeLeZvmU4Uk169o9/vRea6dGro4WrOzOyVwaeDWZbz5xV6N80hE1FIDS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWH4111PDvhy81BiPMRdsSn+JzwP8+1bleE/tAay0+q2mjwvlYUEsij+8en6VMnZXKhHmdjzpXkv9Ra6uHMk0jFmY9ya9D0DT/3CFhXHeHLBmdSwr1XRrXbAgxxiubc9Be6htvpwZwxFa8NsAAMVZghAFWlQAVViHIqLbjHSmSWasc7cfSr+ABSGiwrlEwKFxjNVp7ZGHK1qEA1E8dFh3MCe2ABAHFY1/ZrIhytdbNFkVm3MPXipsaRZwN9YGMEp0rMlh3xkOvIrtb6HBPFYV1EMnikaJHFsWsr1JY/lwwr1/wAM3/m20T5+8BXl+qQg7xiuk8DX+6yRCfmQ7TXRRl0OLEws7nsNncZA5rXt5cjrXIafcZUc1u2k2cc1szlOgjbIqUVQt3ziriHNSA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5P8a6idU8batcsfvXJRfZV+UfoK+r3+430r5A1RN/inUtp+UXkv/oRrKrsb0Fqdt4Ti3ID6nAr0vT4wI1HtXAeEkVLdTnpXfafICorFHZJaGpHwKdmmIeKGcCrMbDqTFM8wUCUUDsPxSEUgkBpGcUARyqMVnXSCr8jVSuDkVLLijAv04Nc9djBNdPfjg1zd8ME1JvE5rWF2xsQOareDZ2ivJUPQ4NX9TGYjWRox8vVTjvWlF+8jnxS0PXNKmyBzXS2UmcVxejSZVa6ywbgV1s886S1bgVpRHismz6CtSHpUgWBRQKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACOMow9q+QtXheDxFqUb53/a5M/8AfRr6+r5c8eWps/H2qIw4a4Mg+h5rKrsb4f4rGv4SmP2dVOc16DpbHaK4PwvAQit26V2P2lrW3JjTe+OBWCO+S0sdGJFRfnYCqdxqVnEfnnQfU1yMlrqWpsTeXbRRn/lnFx+tRS+HLSNSxjMjerEmquQoHWjVrEgn7RHj/eq3bTRXK7oXDD2rzK6tLeLK+UoHtW54Ul+zLsjJ8vsCc0uYp0mlc7nZikIx1qOCUvHuNZGp6p5Dlc807mai27GwWRR8zAfWq08kPTev51wGr3k93cf8fLomMBU60y2s2kXLS3J995pXNPZNHWX2wqcEVzGpDk0jW91H/qbqUgfwucioJpJCds0ZBP8AEOlJmkdNzG1EHjA471k2K7b9GHeuhu0Hlvn0rmbNiNRQe9XS+JGOJ+E9H0NuFrstO6CuK0I9K7TTT0rtZ5h0lkOBWtEOKyrHoK1oulQwJRRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8K+M+nJF4ut7hVx58QYn1IJFev8Aim4lttEnkhYqx2qXHVQSAT/T8a8c1e1g1OBbi0kD+Sx3KOOvXj171lVl0OrDU23zFjw3b4tI8DqK6QW528jis3QI1W3jA6YrqobdZIcN0IxWKR1VJWZgb0ilw25vZFLH9KsTktFlLO4PuQB/WtKXTLJomikgjZD1BFY9x4c0stiO1diewlYD+dOxPMmcprvyn50MRJ4DEZP61seH7NlWLcMZGa2LXw7Y2n71LaJGHcDJ/M81HFcIt8qAjOeBStY19pdWR0McYWDGO1cN4mt5PPZkY/SvRIYd9vuJArkPFNmy/v4yeOopyWhlRl7xzGmJbQBTcPH5zdBI+2uglSRIQy26Mh/uSA/zAqra2kN9BhlVwR0IzSxeHrBWxJb7feNiv6A1JtJ3ZCsiGTEiPGf9ocfmMipL2CMxEjBq9Fo+lwrlIMn1Zif51XvYoo4yIl2iglu+xyl6oBI7Vy1tHjXNo6Lk11eojBNYNvCFv3nJ53YA/Krp6SRnWTlBnZ6KMYrsdP7VyGkDG2ut0/tXYzzTqLA8CtiLpWJYfdFbUPSpYE1FFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvqFst5ZT279JFK59D2P514fe2D2Go3CIDH8rEr+OCv4HmveK4vx/oZlt21KzTMsfMqj+Jccn8uv59qyqRurnVhavJKz6nJeHZQ9tCf8AZFdbbyfIAK4Lw9L5bSQk8xuR+B5FdrZuCAc1jFnXWjqX2i38knFCxqvQVKrjbUbNVnPqVb8nyWC9cVieHzDGmo3c+GliYjHUquM9K2pW3Nisy/0KKVjNE8sUrDDGNyuR70maRatZlHT/ABjBdPJGglQKeki7TUF34ltbi/WwKyO74B2oSBn1plz4ZjihEqlt2cZzzVS90B7YrJC7qxGdwODUam6VPoWbJVtPEc9rCf3ZQOR/dJzW7KK5fRLc2107MSXY5LE5Jrqs7kBpCloyhcZArHvJSAa3rhMisDUFxmkVHU5/UH3E1l2kZkvlGeA2f0rTuwMmotJjDSM/r/U//W/WtKSvJIiu+WDZ02lpjFdVYL0rA0uPpXUWEfSu1nkm5YjgVsw9BWXZJgCtWMcVLAkooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIQGBBGQe1LRQB4h4ltRoPiyWBflt3Pyf7p5X8uR+FbenXeVHNdv4i8LaZr8sUt/HJ5sY2qyOVOOoB/GvMdkumahPY3JzLA2wnGNw7H8Rg1zTi4u56lKqqseXqjsobncOtLLN71jWtxwOasCbc1K4nA0oBubJq1IQEOSAO+ap2z4rM1xZ5VIe8eCE/8APNQAPqTk0yFG7sJq3iXSrWYW0lxEGHXccf8A6qW31vT9TzHDNE5Xj5Hzj61xN54QRpC6vKdxzuDbt1MtfDbW86yRTzI47ilc6VRjbRnYT22ybco4q6h/dA1m2DTpGiT3Mc+Djlfm/PP9K1XwEwKkjyKs8gwawNRbritW6fANYN/JgHmpZtCJi6g21GPtT9KIHy9cGs/U5g0qR8nJycDsK2dBt9+GI5Jzit8One5zY1pQt1Ov0ZAwXg11ljDwKyNGtgAvFamr6tb6FbWrTRyz3F1OltbW0IBkmkbsoJAwFDMSTgKpPaulnmG9bR4Aq6g4r55+KWq+K9N+LF/d+HL+9lstI0KO9udKSZvLniaSRJGVc4Eighg2M/J+FZPhj4ia5pHhXRr1pW1C9j8I3WpGa+uriXzJUuSo3p5oRuP4iu/sGA4qQPp6ivne5+N2vwaPq93broOoRWiae631vDILeJrhgJIH/enLoD1DDocjsItS8Y3/AIs1fwt9sFleQad40itbbUdOjZLe9QQucoGdhkHgkORyKAPo2ivFfhd8VPEHizxdBp+p6dpVnbTLOJLX7RFHeWjoTtVozO0sgIHJ8qPGc8jmue8e6zPoPj34kX9opaVE0RAPPmh4Zyp+aJ0boTxuwe4I4oA+i6K8P0/4q+I5fEcEU9tpL6bJ4suvDnkxwSLNsjAKSCQyFd3PI24OO2eJvhd8VPEHizxdBp+p6dpVnbTLOJLX7RFHeWjoTtVozO0sgIHJ8qPGc8jmgD2qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqvLe2sJIluYUI7M4BogvbWdtsFzDI391XBP5UXHZliiiigQUUUUAFFFFABRWRrOv2elyrBK2+5YbhEp5x6n0HFZ58RXM8TG0gtt5Hyh5GI/lSuB09FcCsmoalI4vrudWU8wodir+XX9af9ijtcywbo5RzvVsH86XMB3dFcnbeL7W2sH/tGQteRkqI41y0g7HHQen4GsifxtqczH7JZQQp28wlz+mKTmluawoznqkehmuP8eeHzqUAvrJf9PgHT/nqn936+n5d6xG8U+ICDj7MP+2R/xrJvr7Wb4t9qvbgqf4UbYv5DFRKpFqx0UsPUhLmTSK2nXQkA557itu2INcgLOexmMsKlkJyyVt6dqEcgwD8w6g9RWKOya6o6ONsDim3qGSAjn6Cq8Fyp71eimQ4zg1RzvQ5WbSLsEmy8+ME8hHKj8qYNJ1DIMxkcehlJ/Su4a6TbtUVUmlGDihotVGzJtbfyVy6gNTppeOtPnk61l3lwEB5qTSKuRX04APNcrq1+I0Y5yewp+r6mASqnLHoB3rLtrGa6kEkoOD0HpU2NU+UqW7yGUySLuJPbt7V1OkanbQbRKsye/lk/yzTrHSgAMrW3a6WmBlRW0askrHNUoQk7s1LPxJptrbSzz3kMUMKF3aRtu1QMk80/wZJJquqN4o1iJoppIzFptrIMG0tzyWI7SSYBbuAFXsc8BeadH4n1p7aJc6Jp0mJ27XVwp4j90Q8t6tgfwmtlVutNfdZysoHVDyp/Cr9t3RzfVub4We1wXKOBzUWuaXY69o93peqQ/aLC7jMU0W9l3qeoypBH4GvPNG8RGQAOdsg4ZSeldtpmpLMo5rXfVHK04uzDV/Cmi6x4et9C1Gy87SoPK8uDzXXb5WCnzBgxxgdTz3zW5TUYMM06gQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAATSF1HUgfWg1BN0oHYsAg9KrX17DZQ+ZO2M9FHU/Ssi93Jkxsyn1U4rltWluXcu07s/QFuahzSLVNvY6c+JkDc2+F9SxH81x+dbNvewT23npIAg4bccbT6GvJ7K9nj1SBLhgYpG2MckDngcfXHetS5E1tdp5DkKvzAEZGMgEH6ZBHtkUlO+xLi4u0jtrjVyxK2Ue/wD6aPwv5dT+lUZVnuebq4dx/cX5V/IVhyX2pLwotx/wA/8AxVEesX8f+vtoZR/sEpj880m2zRSgtjaFvEo2qi8VR+zQ3cW5owCCQR6EHFQrr0BdTNFND2JK7h+nP6VNo91b3AkEcqFmdmCZ+bGfTrSsaKXZkkEt/Yn/AEe4Z4/+ecvzD8O4/A1p2/iOPcFvYHgP95fnX/H9KgZahkhVhgrmhNoHGMt0dLbXMFym+3lSRfVWzU1ee6g1vZyAxs4ueyxHDD8e1OttU1p4yn2kqhGBkBmH/AiKtSvuYzgo7M7W/wBQtdPj33cyx56L1ZvoOprmLzXb7USYrBDaQnq55dh/Jf1PuKzUsd0plnZpJG6s5yT+NacGyNcKBQ5GYWOnRxks5LyMcszclj6k9zVye3QL0wR0IqJZsU2e6+Q80gKtzJskSQf6xflJ9RVC51AfZJXJ/iIH4EisnWNUaK4jVWxlsH8jVO3judXkWC3ysEfDyHoP8TQNJt2RJpsBv7yaYjKjCA+/JP8AMV0UVgiL0FT2FlFZ26RRDCqO/wDOpZnCg1m9Xc7Y3UVEqtbp6Cj7MpHAp0bl2q0gFIq7Rly2QIOVrF1DRgzeZHlZB0I4NddKVRCTz2A9TUSwZGX+8aXKUptHD+ZdWp2yAvjv0P8An8qsw6sFYAtg+h4NdLcWEb5yorNuNFicEFcj0osyudPcrjVlxyf1qKXV0A5P61WbQInkAUlc+hxTD4chLEMXOPVjS1KXKVr3XkUEA5P1rKkuLu/JESEA/wARrpbLw9a5+WMZrah0iOIABQBQojdRLY4iy0HB8ybLOe5rctbNFOMAMO1b72qqOBVG4iKEMnDDpVclyecjjhCmsjxHfXMs8Gg6NIY9SvFLSTrz9jg6NL/vH7qDu3PRTV3XNZh0rSTeNG00zOIYbZCN80zcLGvuT37DJ6Co/Cmky6dBNcahIk2rXrCa8mUcFsYCL/sKPlA+p6k0krEyd9Ea+maXa6ZptvY2MQitoECIo549Se5PUnuTmoLy1BzxWpGeKZMuQaAWhxl7C1vKJYuGX9R6V03hvUt2whuDWfqUIIbisrSJzbXrRE/K3zD6960pSs+UyxEOaPP1R7Pp1yJEHNaIOa4/QbzcoGa6yB9yit2cJLRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKDQAxjVWduKsOcCqNy3BqWUihePwa52/wAEmtm8frWDeN1rCR0wRg6hHnOOD29jW9autzbW0wO4T+Y2fYo2P5CsO+bCs3oM10FvEIFsYP8AnlAxP4IQf50qfUnEdDdkgU9qia3HoKuMaQc1qcxly2Kt/CKoz6UjZyo/Kuj2A0xoxTA5iO1ntjiCWVB6Kxx+XSpwL2QYe4lI/AfyrZaME9KVIhmgd2Ztpp4UjjmtaG1UL0qaNAop5OBxRcRSnhABxVFsqa1JuQazbgYzSAhkkx3qjc3WFOTUlw2BWHqE2FPNMCKytYtW15IpyxijRpGCnGcYGM/jXaIkdvAI4UVI1GFVRgCvP/Dms2thrF39qEu4oqq6rkDkk57+ldNceItN2gJdIzEZ2jO78utTK500rWLrXoDFWPIqFrlZSQpziuV1HWohIZQsioOrEZH6Vc8N3f20SSqQU3YUg9ah3R0Qs9UdPbrgZq0KppMissY3NIeiICzfkKluGuooXb7BdH5cggA/oDn9KEiZSSerBCZ7kt/yzj4Hue5/pVw9KwtH1/T5tU/sdftC3yRecVaB9u3OOXxtz7Zz7UzVvF2k6XqLWN2dQ+0DbnydNuZk55HzpGV7+vFbJaEtm6RUTjg1Q17XrHQoYpNR+1bJGKr9ntJrg5HqI1Yj6moRrtlcaDJq8ZuRZKjvlrWVZMKSD+6Kh+x4289qXKFzOuLkRFGY4GPWmLcSSAScKvUe9c82u2Ws28v9n/ayYFUt59nNBweOPMVc9+lQT+LtNe6XT4WuzcK3ln/QpgmR/t7NuPfOKiSOiNmddZXwhvE7qc7hXTgh0DKcqRkGvKF160026ifUXuv3qMyCCymnxzjkxq2PxxXZR+I7aw0hLu8Fx9i2KVeK1ld8HGMxqpbv6cd6qK0M6m5uTLxzWXfOkMbyTOscSKWZ2OAoHJJNSaJrdjr1s8+nG5MSNsJntZYDnGeBIqkjnqOK4bUNXtfGevWuiQRagmjhPtF089hPCt0QeIMugAX+Js4yMKM5bF2M+Yd4dV9W1hPEd9GyWe0x6dC4wUjPWcjsz9vRMdywruGXBrmNa8SaZp2oGyuvt3nDH+q0+4lTkcfOiFf14pNY1ePTpIFumudzFYofJikkySTydoOB05bjis6keppTs9LnTJMofZnmrPUVyt3e+Xd2t0flBBjkHTnqDWzo98187Oq4gA4J6sfX6Vlc0cbDNQj4NctqGYJFlGflbJ+neu2u4tymuc1K1JU0XtqCSlozV8N3wJX5q9H02YPGvNeJaTO1jdiJjx1X6elenaBqKvGozXYmpK6PNnBwk4s7AUVDBKHAxU1IgKKKKACiiigAooooAKKKKACiiigAooooAKQ0tNPSgCKQ8Vn3TcGr0p4rNuz1qGXEyLxutYd2etbF6etYd2etYSOmBlTjfIqf3mC/mcV0qnzL2YjqsDJ+LkAfyNc1uAu4faRf/QhXS6SPMldj/wAtJR+Kx85/77OKdPZmeI3RvOaRGqOVuaYGrQ5yyZKaZMioGNML0ATM4p0RyeKrdTVqBcAUAWO1IaM5pKBEUprPujgGr8nQ1l3xwtCGZd4/WsC/bOa2r3ha56/cBlTPzOcADqfoO9NAZ2nQD+1XLDIkUH8uP8K1dQ060aImZFwOcnjH41astC1CeeB4bV02g5aVSoAPt1rorTQ7i1ukupIjcSJ90MoAX3AyefzptgcjZeENV1FAbOFYLdlK77liu4HuBgn8wK6PRvBt5pVqsMkscoBJLhmA/wC+Rg/rXZ2FwZU+eN4yDggir46UnqNSa2OV02R9HJi8lCrfM20Hc3qcnkkehJ+vatz7eskYZGBQjP1pdRshcxHb8rj5lb0NctPcNayyRv8AIRy0Z/hPqPUGgRp6hb29ydxQbh0YcMPoRyKoRTPBdRwSM0iScKzdVOM49xx/ntUl1PyYDI2ACQBk4pLG4jmuftMz/dGI1AJPPU4H5fnTRpTvfQ2iOKz735iI/wCHGW96nkugeUilf/gOP54qrZW0usXLfKY7XjJB5f2+n86pnQ5KOrMi6t5b0NDZxiQ8gtnCj6n/AArJuPCetwxu8YtZN3JUsy/lxXrNtaQWUIVVUADjiqeo3ihGAxUPUy+sT6Hk2g3klpq62N9btbTbCArHg/Q9D0rr41MaAKNyDpzyK474iTgPp8iEC5SfKY67cc/h0rrtMl8+whk/vKDVJaG8Zuorst2cu2ZU5AfPyn1q3MvFUmGVxVy3l82LDffHB9/emDM+aP1rOuIk85C+QAcbh2z3rbuUrH1EYgfHUjAoaurBF2Zi+K7MwWUZkcPmZc4GBjBFbXhtwLVRWb4oYz6Akp5ZWUt9QeaXw7P+6WuXZnTfmida6hlrKvoAQeK1YTuQVHcR5BptGcXY4fVLc/eXh15BrR8P6oVCZOD3HpU+pW554rmGY2l4T0Rjz7H1q6U+V2fUWIpe0jzLdHsej6iJAOa6KJwy5FeU6BqGGUZr0TSrkSRjmuho801qKRTkUtIAooooAKKKKACiiigAooooAKKKKAA01qcaa1AFebpWZdng1pS9KzLuokaRMS9PWsK8PWty871hXnNYSOiBkXDbPn5+Ug8fWu30qIx8OcmKMKT/ALTfM3/stctp9ubnUbeIdN4dvoOf6Y/GustmAhdgcmRy2fXsP0Aqqa0MsQ9UiV2yaAagklWNS8jKqjqWOAKp3GsWUJw0+c90UsPzArQwNFmxTCcVSi1G3lUvGZXAGflhc/0qm+v2nmbUjuZCOwj2/wDoWKAN+1TccnpVw8cVjW+qXMkebbTZNvYzSBf/AEENVhW1KdSY1tYz6Hc//wATQBoqc049BVCO3vSf393sPpHEAP1zUzWV06fur+Td2yif/E0gJJBwaytSwEyeOaZMNUtpPKvLhgG4WVY12k+4xkfnVXUNE1G7gUS3RuoQc4RVXP1XHI9s0AVYrebWJtliQsI4acjI/wCAjv8AXp9a67RdAtNPQGNA0pHzStyzfU/06VmaRdmx2QXUQRSdqyKCBn0I7GuojkBXjpTAkWNR0ApSq03dTS1IBxUelMJxSFqTNADw1ZmtaNDqcQOfLmX7sgHI9j6itCnK+KAOOtrD7LcBb0fvl/1fHyY9R7/59ausRnGBxW7f20N5AY5RkHkEcEH1BrhdatNRs2aEXbsrZ2MQBuHoSBkGrTNoVElZj9Ru3mmEEIBh/iAY7pPbgH5f5/Tr0uiuUt/nTyiOxrkNJhWEneZYnyAx3Z+nX9P0zXTQysIiplD+hxg1LdzOUnJ3Ll7c9ea5XWtSWCBpGycdFHUn0q9eTuhIY8VztvbnVtRkkfP2eE7VHq3c/wBKRJ59e3c19rRk1BHikx8kbjGF9vWvTvD6hdItvdM1zvxC0uOHSbWSMATNcKqevfP6Cuj0gkWMSnjaoFWl1O2lNONrF1vu89afZ/LcL7gj/P5VEWqS2JNwmOgz/KmUyxOuc1iXQM0xAH7uM/ma1bh2dzFGef4m/uj/ABqtJGI49qj5RxTEY0iiW0urd+Qw3Afof6Vg6DOYZDE5+ZDtP4Vvsf8ASFyOuV/OuUvm+y6uSOA/P4iuaqrSOmlqrHpGnzBoxV2TBXJrl9IvPkU5rZR5LttqHag6tSuZuNmVL9wzbI13N7Vz+oaeWBLgc12Rto4Uwo+pNc5rl2kfyLy7cBR1NS0a03roYemzta3Qic5/un+lek+Hb/cq815fNY3En7wnYwORt7V0PhjUm3+XJ8sq9R6+4ropVOZcr3OPFUOV88dj2C3kDoDU9YukXQeNea2VOa0OMWiiigAooooAKKKKACiiigAooooAKY1KWA6kCoJbmNOpJ+goGNm6Gsu76Gp7i/A+5E5+pArKub2RsgRKvuXz/Ss5NGkUyleDrWJdDrWhdSTuT86Af7Kc/qazpLd3PzySMPwH8gKxkdEUyxoiiKO9uv4kTYn1P+RRc6zBbosMBWRkG3OeBj9T+FVRZfIUIYoTnazFhn6GpFsiFwoAHoBimpWVkRKlzSu2U/7Ymil80W5mkH8TqRj/AHR0H+ea0ovEcToBdxsoPXK5xUJ08moZdNJB4pc8g9jDuaPlWF8oktnQE8gqaZLDMqgTr9oQdD/Gv0b+hrBkspLeQyQOY36nHQ/UVp6Xqzs/k3K4b69fpVxmmZTpOOvQ2tIuFhA3SZjJwJMY59GHY108AV1DcZ9RXHXB+zlp413wuMSx/wB4ev1FXdM1A27pCz74XG6J/UelUZHWDaeGANRSQhTuXpVUXW4AipYroH5TQBPhJEKSgMp4INVRbNb58liV7A02eYxv7U5LrIweRQA2TybqNlkAOeCCKoWNw9ldGzlJMZ+aFj6dx+FM1TzLaXz4smJvvex9ap30purQSx8TQsJF98dR+IyPxpgdEbgY603zx61jx3W+IMDkEUhuT60gNnzvenCb3rFFz7077V70AbQmHrSGUY61jfavej7V70AajT4PtUN35d1C0cgBB6VS8/dShs0AQCzXgZwy9G7ipZLALAfI4Pp6U/knNWrc5GGoA43Wrx1sngIxdFxGo9z3/Lmjz4tFs4EbjEZbHdiMcfU1Z8T28a69YSk8YbI/l/X865fVrn7TqjXL/MmPLUDsnt+PNMuEOZmW015qmrQ3epv+6iGyKJRwvqfcnua62LULdIgobGBjkH/CuH0m9lXX7jS7995w1xZSlAvmxEjcvHG5Dge6lT1zXRlcCk5tHZShobH9o2/P72P/AL6H9anhvIyTsk2g8F8dB7f41zrKD1FM8tR0G3/d4oUzTkOxSWAR7YXUj2OTUcrDYQxrkwHHSRx7E5/nUouLpR8soPtVKaJcGi7ffId/90hvyOa5nxnAyMJk6qdwreia4vo5UEeWUYJB45qHxJCJYWBFZ1GmVG6M7w3drLGgzweldzbTrHECSAK8i0O5azu2iY/KGwPau5Est4ixxsVU9SOtRKPI7FJqormhqurvNJ9ns1MkncDoPqajsNIcMZrn5pm6k9vYVq6PpsVtHwoz1zWoyDHApWvuDny6RMCe0wOlYV9bvBMtxBw6HP19q7GZARWTeQg54pbaoqLvozc8M36ywxsDwwrtrWTeoryXw/ObS/e2P3WO9Pr3H9fzr0nS59yCuuMuZXPMqw9nJxNmikU5FLTMwooooAKKKKACiiigAooooArzdqozc5q7N2qq4qGXEz5VJqrJDWm6ZqB0qGjRMy2twT0pv2celaJjppSpsXcoiAelOEIHare0UhAFFh3KxiHpUMkYxVp2xVaZ6QGbcRA54rGv7fbhlJBByCO1bsxzms67+6RUM0Q7Rr77RCY5sbh8rfWo3ZollhJ/493Eif7p6j+v5VkLIbe8BHCvwfr2rYkYTSwP/wA9FMbfiP8AECtYSujkqw5ZWOj06cyRgE9quEkHIrB0GbdEoJ+YcH61tMciqMyxK3mw/wC0KrxycUI+GxmqsjhJiAeDQBpq2+Ig4Iqk0caZ2AAHsKeknyHFVBJmQimBnWr+WZIs8IxA+nb9Ke0nPWopOL6b6g/pQ1AEgkNO8w+tQCnCkBL5h9aUSVATio2kxQBoxS1YWVR1NYgnI70vnk0AbbXQFMF/tPWsRpTVaeYhTTAqa3qDXmsNsJ/dLsHsTyT+WKzZEywA6CnaehInmYfM8jAfQEirCR/Nk1LZ20YWjfuYmtaVJfwp9kdYtRtj9otJW6LIOMH/AGWBKkehNaGiajHq+mx3SRtDJkxzQv8AeikU4ZD7gg/XrVsfLdIe2CK5/WT/AMI/rY1dCBpt4Vi1Be0b/djn9uyN7bT/AAmlubJ21N8ikOB1qSKOa6crbRNIR1wOB9TWxZ+Hhw99JuP/ADzQ4H4mkNzOfBMj7IkZ3P8ACoya07PRbiUhrphCn90csf6D9a6aG3it4wkEaxr6KMUjjBpE8zZWjtobW38qBAq/qfrXO6uM7ga6OZuDXO6rzmpZUTz25i8vVZAOjYNdZ4cuWSYRuc9wT3Fc5q4230b+vFatqG8pJoxl4+ePTvXQ1z00+qMIy9nVaezPS7WQNGCKshsiue0W9WWJTnrWu8jEbY/vHv6VgmbSjZ2FuZFTg8seijqazbhZX5KhB78mtCOJYwcZLHqx6mmTLkUhp2OZvw0MiTx/fjbcPeu+0K4Escbo2UZQwPsa4+/iyCMcVq+BJ8xS2jH54Gyv+6f/AK+a0oys7GeKhzRU+x6HA2VFTVUtT8tWxW554UUUUAFFFFABRRRQAUUUUAQyjNVmWrjDNMZM0mikyky1BIKvulU5lxUNFJlVzioWYCny8VVdqhmqHs+KheSo3eoHepZSRI8tVpHprvUEj0rlJDZX9Ko3ByDU8hqvKcioZaMi9UMCKs21wTZRuTlkcE/UHJ/z71DeYANZ8dz5RdM/K/T/AHh/9bP5CinK0rE1o3jfsdVYuYNQuI+2/I/Hmuhjk3IDXK3MmLuKYf8ALWJW/StizuMoOa6DhL5kwwqley7ZM06STmqF/LkjB5pgaltNuSoQ/wC//GoLF8JzUZk/0jj1oAfId17L+A/SlIqG3be0rk9WP+FTbhQAYprHFOyDTHHvSAid6gYk1MyihUFMCDaTTgjVaSMGpRDx0oAo7TUF3GfJY+grUMNU9WIhspGI5xwPWgDEtOLZc98n8yaeXwcDkngAd6v6bod5cRoHHkRAAbnHJ+i/44rpdP0m1sSGjTfLj/WPyfw9Kg9DmsrGRpOg+YDNqKkZHyxZII9yR/Kr03h3SpoJIZ7RZopFKOkrFlYHgggnFbBrwTWdZuYPHF3AmvaoPBb61DDd3oupA1vdbHLWySbsrCW8vcRjbnA9aErmblY9T8G2t9pdrcaNexu8Fg4Szu2IPnwHlAe+9PunPXAb+Kt8ivET8RtR03V5rMXGl2FtP4h1OykvNRaedIkhRGQ/PMNuS2NqkL02qO+E3i/Xb3xBYeLEtbOz1WPwjc3bw3ELtE6x3DdF3BgGVQRknG7vT5RKaR9ENUL+9eOax8VtZgQTQ2mnQMNOsb2CznR2m1JpwpdYCGGNmSPuscimSePdTsLvUokS0s45PET2D3t/JNNDap5atlg0uATkgBWReOBS5WUpo9auOhrn9TOQa5f4GNn4doSwYm8uckDAP71q6TUm61nLR2N6burnGa6PnVvR62fDz7ttZGu/6sn3H860vDbcrXVQ+E5MUveN6aF9MkE0YJtZD26IfT6Vs2V8HUc1o6ZBHcW5imQPG4wynoawdb0i50OXzod0mnseG6mM+jf0NY1YcrujehWVRcktzcWXNKxzWNZXu8DmrrXcca5kYKPc1lc25WgukBBqroM62PiK2djhJj5Df8C6frimvqdu/HnxDPQbhmszUGJUlSQRyCOxovZ3L5OZOL6ns0IwKsrWX4dvRqejWl4MbpUG/HZhww/MGtQV2XvqeO1Z2YtFFFAgooooAKKKKACiiigApCKWg0AROOKpzrV5hVWZallIyLgEE1RkrUnTrVCVayaNkyjITVdzVqVaqyCoZoiBzULGpHPtVeQ1JaGu1VpG96dIfeqsjGpZaKV83WsWUeZKi99xP0wpNa93yDWVCrPfwRqMs77B9SCP60o/EgqfAzqL04FiOjLbrn8qt6fL8vWqt8Q97Mw6IAg/Cksn25rrPNNaSXis2Z90lSTy4SqaPukzQBprL5UOT6VAJdsbynrjj61Tmm81wingdaa83mOqL9xP1NAF+GTbGFFO8w5qsjgVIZAaAJvOIHWmNce9Qsc1GRQBMZ/elE/PWq4U08Rn0oAtxXOKsC9GKoCM0FCBQBfN8oGSaTT431O/ilKn7JA24sejMOgH0PP4VW0fTjqU7vMSLWNsED+M+n0rrkRY0CooVVGAAMACpbNacL6sdRRRUnQIax4fEuhXGonT4Nb0yW/DtGbZLuNpQy/eXYDnIwcjHFbFeN+GPhvqs+s3l1rsyWVlb+J7rWbW3SNXkn3Y2OZQ5Cof7m0NxyeRholt9Dsr/UvBWrXNlrlzrGjzvo7F4bpdQUJbmUFcnD7fmCkDdnocVp3XibQbXT7e/udb0uGxuSRBcSXcaxy467WJw34Vw+lfCG10jw1oNnp97bRaxpV4L3+0PsAxdMrOVEyBwWADkA78jsRnFGj/AAtl0K/sNV0nW4xq8DXDSvdWZlt5POOW2RCRTHg9MOffOaNAXN2O3k8Q6KNQhsDq+nC+nVWitjcp5kgIyCq5yQRyMVTHijQJZLqOLXNKd7VS86rdxkwqCAS4z8oBIGT61yVz8K0m8UT6s+oxTx3F5Ffy288dwVWdOrR7LhFHfG9XK9MkcVSh+FstvYX9i2q2raZcwiJdMFtcfY4280SGQRtclg2RxsdAPQ0rIpOXY7S21bT9WtmuNJvrW+gVihktpllUMADjKkjOCOPesu/70zwzo13oGlzWt9q9xqkjztKskxYiJTjEa72dtoxxuYn3pNQfg1D3OiF7anL62R5ZHqw/nV/w6MOtZesnc6L6tmtnw8nzrXVQXunHin7yPSdC+6tdXDEssRSRQyMMFSMgiuX0NeFrqfPitbR553VI0XLMxwKpnMcJrfh9LPVljsJMwMN8keeYx6A+/aoLm002O5hGyNXk4CuMlvzqK01iW6VzFG89xKxdvTJ9T6VNbaVd/aHvLuXEpGFCgYUelcbs3oetFSilzMS9tkSM7UUD2Fc/dPgMDXRamXEIPGe+K5a+fIJqGbU9T0f4UTGXQLmM/wDLO6YD6FVP8ya7auR+F9obbwssrDBuZnl/D7o/9Bz+NddXXD4UeTXadSVgoooqzEKKKKACiiigAooooAKKKKAEYVBKKnaoZKTGihMvWqEyVpyjNVJUqGjVMyZkqlKvNa00dUpY+tZtGiZmSLVWQVpSpVSVKho0TM+QVUlq/MAM1nXBqGaIpXPSk8OQh9Wadx+7tYmlJ/2uij9T+VQXkgAOTV/TlNv4fLniS9l4/wBwcf4n8adNXkRXlaFu5KpJiLN1Y5NFu2M0jnbHiod2FwOtdJwk1xNk4HSqzylRgdTSYJbABLHoBVufw/rIt/OGnXBjIzkLlv8Avnr+lMCgJGJ2IfqasxRkKMVSjby2KsMMDgg9RVuO6UcGkBLlhTlY01ZkbuKkBU9CKQDg9PV6FQGpRAT0piFQirUe01U8plpGk8pSzsFA5JNAGmI0NV78xw27NuHSs+O7lu3CWgyvdz0rbs7KCORJHzLKvRn7H2HQUm7GkKTkaOiRG30u3jddr7dzD0JOT/Or+RVVZPenh6i502sT5oqMMKUMKAFlkSJC8jKijqWOBWeda03OPtsJPs2aj8QuVsWZVR3HRWP6j3qhok8M9uF06FFjXh5JByW78UrlKOlzcimjnjDwyK6HupyKGNQQyxbniR1Z0wWwOmaHkA70BYV2xVOZ+tLLLVOaTg81LZaRSvH4Nc9qEnJrUvpuDzXN382MkmkapGPet5l6oHRRmur8Ow/MtcnaKZrgv/eNd74eh5Xiu6CtBI82tLmm2dvoseAtJ40WQW1ixz9lEh8wdt2BtJ/8e/EirmkR4UVe8QWB1Hw/eWqruZ0yq+pUhgPxIqJq6sKlLlmmzjLS+jglChVAJx+lWrvUF2/O6qvua5iG0tzMqieZG+6RuORjsc9K3bfTLK3w5Akf+83zH8zXKmz03GKdyJ9s9u7K+9GJKmuUvYnedYYhmR2CqPUngV2zgFSFHFYOiW/neMtNixnE4fH+7lv/AGWk1d2LjLlTfY9d060Sw0+2tIv9XBGsYPqAMVZoorsPFbuFFFFABRRRQAUUUUAFFFFABRRRQAjVE4zUxppFAFV0qB46vlahkWpaKTMueOqMsfWtiZaz5xjNQ0apmXKmKzrggVp3OcH0rKnjkkXdGhMZOPMbhB+NZtGiaW5m3UmM4rCvbtIgdzc+g5Nde2ihlzPIXb0Hyis2+0OIIcAD6UlTb3E66XwnEpLLqF3HbQJhpGCgt6k+lddfxLHdRWkX+qtIwg+tHhzSorO6n1KXAjtgRGD3cj+g/pV200nU7l5JV0+5Mkp3fOmwfm2BWkYKOxhOo57mWULHnpRbWk97eLa2cbSzN2HYepPYe9dbY+DL2eRTfzR28PUrEdzn26YH15rsdJ0qz0mAxWMIQHlmPLOfUnqa0SIMvwz4Yg0hVmn2zXpHL44T2X/H+VdFRRVAQXNnbXX/AB828M3/AF0QN/OqM3hzRpvv6ZaD3SMIfzGK1aKAOZn8EaJJny4ZoT6pMx/9CzVOTwBZf8sb68X/AH9rD9AK7KilZAcG/gS4TJg1NG9FaEj9dx/lWfJ4X1+E4SKCUeqSgfzxXplFHKgPI5LHVkv3s54445FUEnfnrXSaJo8VtiS6hFxMf4pACq/Reg+vJ96k8Uqo8SwMj/M0A3qO2GOD/n0rRt7iCFFGWd8fdUZNKw7DZdHsJhn7MI29YyU/QcVk6hpLWrI0E7+Uxx84B2n9K6ES3Ev3I0iXsX+Y/kP8alk8to2Rwrqw5U9DQ4plKcl1OUkt7qIZUo498qf14/Wqr37wf6+MqPXqP0rpzpqAH7NdTQg/wkhgPzqu2j3Lf8viN9VP+NS4I0VaXUw4tWhfo4/OrCX8Z/iFS6nonlwGW4aGQL1wgz+ZzVF9Ftv4H2/8B/wIqeQpVl2LFxLBcRFJVSRT2bkVkLp1hFIxjgePcckRzMoz9AafNpDA/u5W/wC+iP6GqcunXQ+7O/5A/wBRScGWq0Ua0EsFvF5cSLGnXAPU+pqOW8T+8Kwhp99P5ghkZvLO1iQBzj61SmsNQjb53kH0Xd/I0uSRSqwOge5U9x+dUrq7QA/MKyPIbGJb7yz/ALUZH9ains4COdTLn0RMn+dLkZXtoDb6+Tn5hXP3k/2lmVM4x2rWbSYHfLvLs9WIBP4VDfwW9pbFLdQGfjOcmnGnd6iliElpuQaRDllr0DQocba5PRYOFOK73RYvu12M4DqtLjworbiGBWdp6YQVpqMCs2Bz3ivw1BrFu8tuqQ6io+SYcbvVW9cjjnOK8+jHlSPb30l+ssR2OhGOR7qP617JVG90mwvpFku7WKWRejMvP51nOnfVHTRxDgrPVHnVncQriNElVP70n/1zmtnwhpEp1+XUpYnjhSMpGWXG5j1Iz6D+ddfbadZWpzb2sEbeqoAfzq3SjTs7sdTE8yaS3CiiitTlCiiigAooooAKKKKACiiigAooooAKKKKAEIqKQVNTWXNJjRQmFVfsss5+ReD/ABNwP/r1riFM5YbvrUlLlHzdihbaXBEweQebIO7DgfQVJdWSTEuh8uQ9TjIb6jvVuinZEt3OL1LTbq3LGKOWNR/zzXzEP0A5H6VlJbvcvsZ55fVIYWyfx7V6TRS5QOV0nQpJpoZb6FYLWA5its5JPq1dVRRTSsAUUUUwCiiigAooooAKKKp6vfx6Zp8t3OsjRx43eWMkZIGee3NAFmdykTFArSYOxWbG5scDNcq+uXusWV3p9vpl7Y6if3EjOy4gDdX3A5PGSMDk1zWpXVxfWDJqizalBaOJjKkSCaHggvtx02k/KUI9HyBWpaXMvhzR2ur+We61O6/dwpcEBxEpbZux6A5PU5OM0m7ajjFydkLqsRl8R3sksmyJdi5JxxsH9a0rO7sokAW4h49HBrjLeKW5lae6cySuxclvU+g7VqwwgADFZe07HV9Xtuzpm1G0PC3UBPoJBUUlwpGVcEeoNYMkAYHisq7tmiJaFijeqnFP2hP1fszqDqflHDHipk1SJxwwrzx9Ru4W2Tys8X97aNw/TmtzS47aZVfzHkz334/lVKSexlKDhubuq38bWMq7xnHrVcXcX99fzq1BptnKMNDG2fUZq4uiWzDi3i/75FMm5jtdxHoy1XmuIz/EK2J9Bt8HEIH04rE1DRFQEx71/wCBE/zosFytaToJLpdw5cH/AMdFEkoz1zWFd2lxbyOY5WGeuRmqLXl3E3zAOPbigZ0kkgYYOMVUkEIB+UVnJq0RU+YSpHY1Xm1UNxFE7D1PFJtLccYt7C3xiwwIx7iuem+a6ADFgPXtWjNcTSf8sv1qhIxEwZoio7kHNEJxuaOlO2x0ujgYSu+0OPO2vPtHcZTB49a9I8P8ha2ZznU2iYQVaFRQD5RU1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWLqGqw/ZJZ4bqI2e0x+fEonRWOfmcDooxz9ecYqbXNQNnazqhMUhjJSdx+7QngZPIHrzx7153oMWpx3Ecd5BFgvtjYZi2k/wDPKaMsuDnOxsDnA4oAv6ba2eqakbg2ulra6aS91c2dyzxXCFGIUIBtAzhiCeNo65zWVcXc2sanJeXGRuOET+4vYf5710XjKSPTNJtdEs3c+YxlkLHLbdxODj1b9FxWHYw7QOKwqSu7Hbh4cseZ9S3bR4AFX40wKbbxZq4EwKlItsrOMCqF0ODWlKOKz7odaTHE5zU4QwJHWsayv5LC6HzERE8j0966S8XINczqsOCWApJ2dzSUFONmeiaHqPm7eea7WzYPCD3rx7whdMUAY8o2K9U0qXMa+hFdSdzzJR5XZl+Toax74rzWncthKwr1utMkwtRjRieK4/WJEiOByTwBXU6lLtVjmuKXN7qLN1VTtH1qJOyNaceZ2HWVj5x3yDn+VaQskUDArQtYAsYGKmMVYPU7opRVkYkluB2qjcQgjGK6CeLisy4jxmpaNFIzdPlNtcqh+4x49jXpnhm5B2jNeazx5zXSeEtQO8I5/eLwff3rppTuuVnHiaVvfR69bNlBVgVk6XOJIwc1qA8VZyDqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACquqXf2HTbm6CbzDGzhc4zgVaqO4hS4gkhlGY5FKMPUEYNAGFqtveFBPPbLLNGp23Fi5jlT22n7y+oJOfSs74eW8H2FL2K+imlmj82cInlt5j/M3mLnBwTwcDA45FabvrFvavYi2N1KVMcN6HUKB0DSKSDkd9oOcds4EHiUW+i+HD9nRBOIVs4pCBv24xjP0BNJuyuOMeZpI4rUrs6prd1dZyjPhP90cD+WfxrQs4+lZWnx4UV0NjH0rmWup6UrRVkXrePC0+TipFGFqOTpVGO7Kcves+4rQm6VnXBqWaRM65GQawNUX5TW9cHrWFqR+U1Juit4Yl8u6mXtx/WvXdDbdbxn1ArxbRGP9oso7kCvaNCXbax57KK6Kex51f42X7xuorEvTwa1bs8mse9PBqzE5XX5fLhcn0NYOgQ8AnqeTWn4pJ8lh7VX0NQFFY1Drw63ZvQx/KKkZOKmgTKinulQbGZNHWdcRVuSJVC4j60FI5+ePBNQW0ps7tJwOAcMPatS4j68Vnyx9aSdndFaSVmeo+HbsPEvOQRXWQtuUV5Z4HvDsaBjzEQB/u9q9Ksn3IK607q55c4uEnFl4UUCigkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuG+JExaWwtx0AaQ/oB/Wu5rzfxzL5viQr/zyiRP5t/7NWdR+6b4ZXqFGxXgV0NimAKxLBeRXRWwworKJ1VGSNUMhqVzVeQ02ZorTnisu5brV+4bg1lXTcmoZtFFK4brWHqT4RjWrcN1rn9Yl2xNUmyWgvhGEzam0pHyq2K9k007YVHtXmngu3EVvEWHzN8x/HmvSbRgsQ+ldUVZHl1XzSbJbls1kXp4NS3l4A+AaozTb161Rmcn4pz5TY9Kj0Q/dqbxOubVz6CqmgtnbWNTc7MN8LOytR8lPdc0lpzGKmZakvqVHTiqk0fWtNlqrMlIpMxbiLrxWbPHzW9PHWbcRUi0yjpNybDWbeUnEbny3+h/+vivX9Ll3IteMahH+7JHUV6d4VvftOn20p6ugJ+tbUnujlxUdpHYocilqKFsipa1OQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKvEsnm+Jr9vSQL+Sgf0r1WvIb9vM1u/fsbiTH03Gsqux1YVe82aWnL0rfh4UViacOlbS/dFZo2nqK5qrK3BqZzxVSdqGKKKdw3BrKuW61euW61l3Ldahm0UUrluDXN6kfOnji7MwB+netu8kwpNYdkpnv2fsvA+tOCux1ZcsGzrtAy0owOK7Uy+VbdecVzugWoijDt1q/qFyAm0Guk8wqySF3Yk9aQP2qPcMU5CKAZm61H5lvIvqKwvD8mCqnqODXS6gAUrmAv2TUvRH+Yf1rOotDowz1aPQLA5jFW2FZWkzB4hWoDkVCNWtRhFQyrVkio3HFAIzpkzVCeLIPFa0iVVljpFJnO30WUYYrqPBMpGlwAnlSy/kxrIuouDxU3hm5FtctaPwHJeM+/cf1/OrpO0jOunKGh6dZyZUVdU1iafLwOa2ImyK3OEkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARiFUsxAA5JNeMtKr3EkoIwzlvzOa9E8cah9k0nyEbEtydnvt/i/oPxrhbfZwDgCsKru7Hbho2Tl3L2lzA4wQa343DLWJDYRuBJA2yTsy9D9auWcziQwzrtlAzx0YeoqUaS12Lkp4qjO3Bq1KcCs+4frQxRKN0+Oayrp+tXrxtyEVgzT4Dqx+Zf5VB0RRn6rPhSo5J6UujRCJhuI45J96z5ZWkuC+zeq9PrVq2uQ5CFSjn16VtCDSucmIqJy5V0Oyg1AJGFFRtcGaTOeK5+MSq3OauJMygAdas57Gq0gAxmgT7e9ZySk/eNI8+3pzQKxcuJ9wINZN9E00R2f6xDuX39qe0sjNwtOEczDcRgDue1J6lRfK7oveHb0MoBNdYj5VQvVuBXnMc6W15uiYMjHL7eQD612ui3YlYEnoMCsrOLszr5lNcyNortUComFTMQ3SmkUyEVnTNQPHxV/ZTTHSKuYtzFhSSOlY1zbNkOSVcHIx/Ca6q4hzgVQurbOeKLFJmz4Z1A3dqpfHmp8r/X1rrbZ8qK838PubXVQhOEmG38RyP616DZtwK6Iu6OGrDllZGiKKRelLTMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio7iQQ28sp6Ipb8hQB514omOo+IJQDmOD90v4df1z+VMgsyAOKZpyGSRpH5ZiST7mtuKPgVzbu56N+VKKMxreSD95DwRyV7GppJBdWwki4mjO5fY+lajxgpWQyfZ7wFfuvwfrQJO5OZRLCrjuPyrOuSeatgbGdOx+YVSujgmkyomZdthTXPSW0l9esI22xgAMR1rZ1KXC4UEseAB1JrY0HRzHCocZcnc59SaqnDmeoq1XkjpuzCg0U7AAmAOlLLoJx9yvR7TTFCjIqw2loR90V13POPJm0q4i/1TyL+NRm31BOjhvcqK9Vk0dT/CPyqu+iKf4RS0Hc8vKal6p/3xSrHqXqn/AHxXpZ0Nf7opV0Nf7o/KjQLs84S21FyMykf7qgVYi0SWZgZi7n/aOa9Gj0VR2H5Vci0pF7UXSFc4G10Ir/BinS2cmlyrMikQNw3+yex+hr0VdPUDoPyqK509JImR0DIwwQe4qZLmVi6c3B3OcsblZFHNXSQMdyayrjTZtIlLgtJadd3dB7/41o2beYgc9+n0rns1ozrumromC04JTwKeBQTcrvGDVS4i68VpMKrTrwaBpnNXx8iRZV6xsHH4HNeh2XQV59rPEb/Q16JZIRGoPYCtKfUzxGyL69KdSLS1ocwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWZ4ll8rQ7sjqybP++iF/rWnWD4xfGmxR93lAI9gCf8KUti4K8kc1p0eAOK2Il+UVRsY/lFaSDArBHXJ6g3Ssu/jzgjqCDWo5qjdYoYolKQHeG7bcVl38mM1pTybUNYNyXuJ1iiGXc4AqTWPcl0OyN5dmdx8iHC+59fwrvNOtAoHFU9G09YIY40HCjH1ro7aLaBXTFcqscNSfPK5JFEABxUhQelOAwKKZmM8selN8palooAi8lfSjyl9KlooAYI19KUKKdRQAm0Ux0BFSUUAZWq2RubC5hTAaSNkBPqQRXK6PLmIKwKsvBU9QR1Fd6VzXKeJreK0voLiEhZJjh4wPvYH3v5Cs6i6m9GX2SVelOApkPKg1LUGgxuKqzng1ZkqjcHg0mUkYV+hnuooR1kkVPzOK9LhXArgtIh+0eIrQH7qEyH8AcfrivQkHFaU9rmWIeqQ8dKKKK0OcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmfGL5ls4x/tMf0x/Wumrk/EbebrAXtHGo/HJP9RUT2NaPxDLNMIKsk4FQRHCinM2azN2JI9ULl+DViUmqNwaTKiZt9KQpq94Y0wk/a5h8zj5B6D1/GqqwC4u4Y3GVZwD7iu5s7cKowOlXTjrcivOy5UTWkG0Dir6jApsa4FPrU5AooooAKKKKACiiigAooooAKKKKACuL1if7Z4hlX/lnbgRj69SfzOPwrtK4GzPmXt1Keryu35sTWdQ3oLVs14hwKfSJ92nHpUGhFJ0qhdDg1oSdKo3X3TSZURPCcW/WZpP7kRH5kf4V2g6Vy/g+P95eye6r/ADP9a6kdK1gtDnrO8xaKKKsyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4/Uf3mr3Ler4/IAf0rsK5aRN99M3rI386iZrS0bI1U4p22rYioaPFRY15jNmXANUZFzmtaaPNUpI8Umiosi0mDzdUtxjgMWP4A128SACsHw1bf6RLMf4V2j8f/1V0YFawVkYVneQCiiiqMgooooAKKKKACiiigAooooAKKKKACvPtK4HPWvQa4JAI765VfuiVwPpuNZ1OhvQ6mvGeBUlQQNkCrIGRUlshkGRVK6HymtFlqldr8ppDiy/4STFnO396Y/yFb4rN8PQ+VpkWerZf8zWmK2jsc83eTCiiimQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVhrF/pEnH8R/nW5VEx4nc+9JlxdiLy+KY6VcK00pU2KuZksdVHiya15Y6r+USTgUrFKRf0mAQ2SYHL/Ofx6fpirlIqhVCjoBilrRGLd3cKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFefpzKz/AN5i35813d0/l20rjqqE/pXGiHDAAcCs5m9HS5Zts8VoxrkVWtouBWlFHxSSKkyBk4qlcR7yFHUnArVdMCo7KHzLwMR8qfN/h/n2p2J5rampEgjjRF+6oAFPoorQwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAComX94T61LSMORQAzFIVqTFNIoHcruuaRI+R9amI5pVHIpDuS0UUUyQooooAKKKKACiiigAooooAKKKKACiiigCvqB/0Vx/e4rEWH5s1uXY3KF/GqnlYNS0aQdkRQRciryJxTYY8VYAoSE2V5V4qS0j8uMnu3NOZNxxUtOxLYUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhFLRQA3bSgYpaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBjKSelN8v2qWigBqrinUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest compressions for infants (under one year) may be performed with two fingers placed on the sternum just below the nipples. This picture shows the site of compressions. When compressions are performed the two fingers used should be perpendicular to the chest and straight.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31184=[""].join("\n");
var outline_f30_29_31184=null;
var title_f30_29_31185="Patient information: Blepharitis (The Basics)";
var content_f30_29_31185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83063\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/5/27731\">",
"         Blepharitis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/40/41601\">",
"         Patient information: Pterygium (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/39/34417\">",
"         Patient information: Stye (hordeolum) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Blepharitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/blepharitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13068516\">",
"      <span class=\"h1\">",
"       What is blepharitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blepharitis is inflammation of the eyelids that causes redness and swelling of the lids. The symptoms might get better and then come back. But blepharitis rarely causes problems with your vision.",
"     </p>",
"     <p>",
"      Blepharitis is more common in people who have certain skin conditions, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rosacea - This causes redness and raised, red bumps on the cheeks, nose, chin, forehead, or eyelids.",
"       </li>",
"       <li>",
"        Seborrhea &ndash; This causes redness, scaly patches, and itching, mostly on the scalp. Dandruff is a mild form of seborrhea. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13068531\">",
"      <span class=\"h1\">",
"       What are the symptoms of blepharitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eyelids that are red, swollen, and itchy",
"       </li>",
"       <li>",
"        A gritty or burning feeling in the eyes",
"       </li>",
"       <li>",
"        Red eyes",
"       </li>",
"       <li>",
"        Crusty, matted eyelashes in the morning",
"       </li>",
"       <li>",
"        Flaking or scaling of the eyelid skin (",
"        <a class=\"graphic graphic_picture graphicRef83051 \" href=\"mobipreview.htm?27/5/27731\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13068546\">",
"      <span class=\"h1\">",
"       Is there a test for blepharitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13068561\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put warm, wet pressure on your eyes &ndash; Wet a clean wash cloth with warm (not scalding hot) water and put it over your eyes. When the wash cloth cools, reheat it with warm water and put it back over your eyes. Repeat these steps for 5 minutes, 2 to 4 times a day.",
"       </li>",
"       <li>",
"        Gently rub your eyelids &ndash; Do this right after putting warm, wet pressure on your eyes (see above). Use the washcloth or a clean fingertip to gently rub your eyelid in small circles.",
"       </li>",
"       <li>",
"        Wash your eyelids &ndash; Use plain warm water or warm water with a drop of baby shampoo on a clean washcloth, gauze pad, or cotton swab. Gently clean any crusty material off the eyelashes and eyelids. Do not rub hard or you can cause more irritation. You can also use over-the-counter eyelid scrubs and pads.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13068576\">",
"      <span class=\"h1\">",
"       How is blepharitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the treatments you do on your own do not help, your doctor might prescribe:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An antibiotic cream or ointment to put on your eyelids",
"       </li>",
"       <li>",
"        Antibiotic pills &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13068591\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34417?source=see_link\">",
"       Patient information: Stye (hordeolum) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/40/41601?source=see_link\">",
"       Patient information: Pterygium (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/29/31185?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83063 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31185=[""].join("\n");
var outline_f30_29_31185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068516\">",
"      What is blepharitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068531\">",
"      What are the symptoms of blepharitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068546\">",
"      Is there a test for blepharitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068561\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068576\">",
"      How is blepharitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068591\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/5/27731\">",
"      Blepharitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/40/41601?source=related_link\">",
"      Patient information: Pterygium (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34417?source=related_link\">",
"      Patient information: Stye (hordeolum) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_29_31186="Polyarteritis nodosa";
var content_f30_29_31186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polyarteritis nodosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous nodules are present on the extremity in this patient with polyarteritis nodosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31186=[""].join("\n");
var outline_f30_29_31186=null;
var title_f30_29_31187="Lichen planus wrist 2";
var content_f30_29_31187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus. Flat-topped, violaceous, polygonal papules on the flexor wrists are present. There are active and resolving lesions. Note the postinflammatory hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31187=[""].join("\n");
var outline_f30_29_31187=null;
var title_f30_29_31188="Oxazepam: Patient drug information";
var content_f30_29_31188=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/50/10022?source=see_link\">",
"     see \"Oxazepam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxazepam&reg;;",
"     </li>",
"     <li>",
"      Bio-Oxazepam;",
"     </li>",
"     <li>",
"      Novoxapram&reg;;",
"     </li>",
"     <li>",
"      Oxpam&reg;;",
"     </li>",
"     <li>",
"      Oxpram&reg;;",
"     </li>",
"     <li>",
"      PMS-Oxazepam;",
"     </li>",
"     <li>",
"      Riva-Oxazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat alcohol withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or psychosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10934 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31188=[""].join("\n");
var outline_f30_29_31188=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204465\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263493\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013548\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013547\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013552\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013553\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013555\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013550\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013551\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013556\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013557\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/50/10022?source=related_link\">",
"      Oxazepam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_29_31189="AGEP detail";
var content_f30_29_31189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthemous pustulosis (AGEP) detail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Nonfollicular, pinhead-sized&nbsp;pustules on a background of edematous erythema are characteristic of AGEP.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Werner Pichler",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31189=[""].join("\n");
var outline_f30_29_31189=null;
var title_f30_29_31190="Grief and bereavement";
var content_f30_29_31190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Grief and bereavement",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     Susan D Block, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31190/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/29/31190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 2,500,000 deaths occur annually in the United States and between 5 and 9 percent of the population sustains the loss of a close family member each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Loss of a close relationship often causes profound suffering and can have important effects on health status.",
"   </p>",
"   <p>",
"    The vast majority of bereaved individuals (80 to 90 percent) cope with their losses without requiring professional intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/3\">",
"     3",
"    </a>",
"    ]. However, bereavement can have serious and long-term adverse health effects, and patients often consult clinicians for help in managing distress associated with bereavement. By understanding both normal and dysfunctional grieving processes the clinician can appropriately reassure individuals with normal grief responses and intervene to help those experiencing dysfunctional reactions to loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL BEREAVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death is the most powerful stressor in everyday life, causing both somatic and emotional distress in virtually everyone closely tied with the person who has died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/4\">",
"     4",
"    </a>",
"    ]. The effects may be intense and long lasting.",
"   </p>",
"   <p>",
"    Our culture uses three discrete terms to talk about the loss of a close relationship:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bereavement is the reaction to the loss of a close relationship.",
"     </li>",
"     <li>",
"      Grief is the emotional response caused by a loss including pain, distress, and physical and emotional suffering.",
"     </li>",
"     <li>",
"      Mourning refers to the psychological process through which the bereaved person undoes his or her bonds to the deceased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anticipatory grief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grieving is thought to begin when an individual is forewarned of an impending death. Anticipatory grieving may take the form of sadness, anxiety, attempts to reconcile unresolved relationship issues, and efforts to reconstitute or strengthen family bonds. Caretaking behavior may be a form of anticipatory grieving, as the caretaker expresses affection, respect, and attachment through the physical acts of providing care. Anticipation and an opportunity to prepare psychologically for death is thought to ease the adaptation of the grieving individual after death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal grief reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately following death, whether or not it has been anticipated, survivors often experience feelings of numbness, shock, and disbelief. They \"go through the motions,\" taking care of funeral arrangements, greeting relatives and friends, and tending to financial matters. However, the reality of the death has not been fully comprehended. Shock and numbness, intense feelings of sadness, yearning for the deceased, anxiety for the future, disorganization, and emptiness commonly arise in the weeks after the death.",
"   </p>",
"   <p>",
"    \"Searching behaviors,\" including visual and auditory hallucinations of the deceased person, are common and may lead the bereaved person to fear that he or she is \"going crazy.\" Despair and sadness are common as it becomes clear that the deceased will not return. Sleeplessness, appetite disturbances, agitation, chest tightness, sighing, exhaustion, and other somatic complaints (especially those similar to the symptoms of the deceased) are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survivor often replays and remembers the relationship with the deceased, particularly the events of the terminal illness and death, and commonly ruminates over regrets and missed opportunities. Anger at the person for dying, at God, and at professional caregivers may occur. The individual may withdraw from family and friends. Being with others and being alone are both difficult.",
"   </p>",
"   <p>",
"    Grief comes in waves that are often precipitated by reminders of the deceased; the bereaved may feel fine one moment, and be overcome with sadness and grief the next moment. Feelings of pleasure are often experienced as a betrayal of the relationship with the person who has died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Normal grief resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distressing feelings gradually diminish in intensity for most bereaved persons, usually over months; the grieving individual slowly comes to accept the reality of the loss, reestablishing mental and physical balance. Similar to stages of grief in dying described by Kubler Ross [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/6\">",
"     6",
"    </a>",
"    ], resolution of grief, to some degree, occurs in stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/7\">",
"     7",
"    </a>",
"    ]. In the early phases after a loss, the intensity and symptomatology of grief can overlap with signs and symptoms of complicated grief (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Complicated or prolonged grief'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    These signs and symptoms, and their intensity, subside slowly over time for patients experiencing normal grief. Usually, these impairments are beginning to resolve by six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the loss becomes more fully accepted the bereaved begins reorganizing his or her life and reinvesting in living. The bereaved person slowly becomes able to remember the deceased without being overwhelmed by grief, can work productively, can sustain a sense of self-esteem and purpose, and can carry on with pleasure and enjoyment. Anniversaries and important events continue to precipitate waves of sadness; the amplitude of these waves diminishes over time, although the grief may never go away entirely.",
"   </p>",
"   <p>",
"    There is considerable range in the duration and intensity of the bereavement process. Some variables that may have an impact are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age of deceased &mdash; The death of an elderly person after a full life will have a different impact than the death of a child or a young adult.",
"     </li>",
"     <li>",
"      Pregnancy and newborns &mdash; Miscarriage or death of a newborn are often not recognized as major losses but can precipitate prolonged grief.",
"     </li>",
"     <li>",
"      Suicide &mdash; Bereavement due to suicide or other socially disapproved deaths may lead to more isolation and to increased vulnerability to suicide among some survivors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ABNORMAL BEREAVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care clinician is in an excellent position to prevent both physical and psychological morbidity associated with bereavement, and to help the bereaved individual adapt to his or her loss. Despite experiencing worse health, persons with abnormal bereavement are less likely to use health services. Thus, outreach efforts are particularly important in identifying individuals at risk and preventing the adverse effects of abnormal bereavement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors for poor bereavement outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for the development of poor bereavement outcomes have been identified, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor social supports",
"     </li>",
"     <li>",
"      Past history of psychiatric problems, especially depression",
"     </li>",
"     <li>",
"      Past history of childhood separation anxiety",
"     </li>",
"     <li>",
"      High initial distress",
"     </li>",
"     <li>",
"      Unanticipated death, lack of preparation for death",
"     </li>",
"     <li>",
"      Other major concurrent stresses and losses",
"     </li>",
"     <li>",
"      History of abuse or neglect in childhood",
"     </li>",
"     <li>",
"      Lifestyle rigidity (aversiveness to lifestyle change)",
"     </li>",
"     <li>",
"      Highly dependent relationship with the deceased",
"     </li>",
"     <li>",
"      Death of a child",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Psychological sequelae of abnormal bereavement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression, suicide, anxiety, and complicated grief are the most common adverse psychological sequelae of loss. Rates of depression during the first year after the loss of a spouse, 15 to 35 percent, are four to nine times higher than the rate in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/9\">",
"     9",
"    </a>",
"    ]. Suicide rates after loss of a spouse are elevated, particularly in older men and in the first year",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/2,10\">",
"      2,10",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Complicated or prolonged grief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated/prolonged",
"    grief is a syndrome with characteristic symptoms and risk factors, a predictable course, and outcomes.",
"    <span class=\"nowrap\">",
"     Complicated/prolonged",
"    </span>",
"    grief represents a disturbance of attachment associated with an unstable sense of self and insecurity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Complicated/prolonged",
"    </span>",
"    grief is defined as the persistence, for at least six months, of a constellation of disruptive emotional reactions including yearning and four of the following eight symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Difficulty moving on",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Numbness/detachment",
"      </span>",
"     </li>",
"     <li>",
"      Bitterness",
"     </li>",
"     <li>",
"      Feelings that life is empty without the deceased",
"     </li>",
"     <li>",
"      Trouble accepting the death",
"     </li>",
"     <li>",
"      A sense that the future holds no meaning without the deceased",
"     </li>",
"     <li>",
"      Being on edge or agitated",
"     </li>",
"     <li>",
"      Difficulty trusting others since the loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other indicators of complicated grief include social withdrawal and difficulty reengaging with life. Symptoms of",
"    <span class=\"nowrap\">",
"     complicated/prolonged",
"    </span>",
"    grief at six months post-loss are highly predictive of impairment and complications at 13 and 24 months post-loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bereavement related depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many patients with",
"    <span class=\"nowrap\">",
"     complicated/prolonged",
"    </span>",
"    grief also meet diagnostic criteria for major depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    generalized anxiety disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/15\">",
"     15",
"    </a>",
"    ], only a small minority (&lt;20 percent) of patients with bereavement-related depression are treated with antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/16\">",
"     16",
"    </a>",
"    ]. This observation probably reflects the belief, on the part of both patients and clinicians, that depression is an understandable part of the grieving process rather than a psychiatric disorder that can be treated and ameliorated. A full depressive syndrome that occurs early in the grieving process is likely to result in prolonged and substantial morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of major depression in a grieving person represents a clinical challenge. Helpful clinical clues to the diagnosis of major depression in this context include generalized feelings of hopelessness, helplessness, worthlessness, and guilt, as well as persistence of the initial and severe symptoms of early grief (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Normal grief reaction'",
"    </a>",
"    above). Treatment with antidepressants and psychotherapy represents a reasonable diagnostic and therapeutic approach in equivocal cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medical sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bereavement is associated with higher rates of mortality (especially among older men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/10,17\">",
"     10,17",
"    </a>",
"    ], morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/2\">",
"     2",
"    </a>",
"    ], health care utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/18\">",
"     18",
"    </a>",
"    ], consumption of alcohol, tobacco, and sedatives (increases ranging from 25 to 30 percent in some studies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/2,19\">",
"     2,19",
"    </a>",
"    ], and impaired immune function (although this finding is of uncertain clinical significance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with congestive heart failure and hypertension are at particular risk for disease exacerbation in response to real or threatened loss of a relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, increased substance abuse may contribute to the rise in disease-related mortality and suicide among the bereaved. Patients with continued symptoms of complicated grief six months after a loss may be at increased risk of cancer; hypertension; heart disease; changes in eating, smoking, and drinking habits; hospitalization; disability; and reduced quality of life over the ensuing one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CARING FOR THE BEREAVED BEFORE THE DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician's role in assessing and managing the bereaved ideally begins before the death takes place. Attention to family members during the dying process offers the clinician an opportunity to assess both the coping resources and the vulnerabilities of these individuals. The clinician should consider referring individuals with poor coping resources and risk factors for poor bereavement outcomes for psychosocial support before the death.",
"   </p>",
"   <p>",
"    In addition to offering direct help to family members in anticipation of a death, attention to the quality of the dying process also influences grief after the death. Preparation for death clearly facilitates bereavement adjustment. Helping a patient to \"die well\" reduces the burden on the family during bereavement. Dying well has different meanings for different families; for some it might mean aggressive, high technology care up until the last minute; for others it might mean having the opportunity to provide supportive care in the home with many family members participating in the process. The opportunity to participate in providing care has a positive effect upon bereavement outcomes.",
"   </p>",
"   <p>",
"    Expert palliative care clinicians can be a resource in facilitating a \"good death\" for the patient, and in addressing family concerns. Hospice use by patients is associated with decreased bereavement mortality among surviving spouses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/22\">",
"     22",
"    </a>",
"    ]. Caregivers of spouses with longer hospice enrollment have a lower incidence of major depressive disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, family members should be supported in their involvement in providing care and should be encouraged to be present at the time of death.",
"   </p>",
"   <p>",
"    Conflicts between the patient and family or among family members about the type of care desired for the patient often pose particular difficulties for family members after the death. Similarly, feelings of guilt and doubt may color the bereavement experience when family members are required to assume responsibility for discontinuation of life support or other treatment withdrawal. The clinician should provide family members with appropriate information and support to guide decision making and help prevent negative sequelae in these situations. Clear recommendations from the clinician about difficult treatment decisions are often helpful in situations where family members are distraught by difficult choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARING FOR THE BEREAVED AFTER THE DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician caring for the deceased can facilitate acceptance of the death with attention to several follow-up recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should contact family members not present at the bedside immediately after the death via telephone to inform them, express condolences, answer any immediate questions, and offer them the option of viewing the body.",
"     </li>",
"     <li>",
"      A letter of condolence is a core component of quality end-of-life care. Attending the funeral or memorial service is usually deeply appreciated.",
"     </li>",
"     <li>",
"      The United States Preventive Services Task Force (USPSTF) recommends that clinicians \"be alert\" for suicidal ideation in people who have had a recent bereavement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/24\">",
"       24",
"      </a>",
"      ]. Reaching out to bereaved persons, through a personal phone call or an offer of an appointment to \"check in,\" is recommended as the bereaved often find it difficult to initiate actions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients should be encouraged to maintain regular patterns of activity, sleep, exercise, and nutrition as much as possible, as these activities appear to enhance adaptation during bereavement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most grieving persons do not want or need professional help in the grieving process; instead they turn to family, friends, and religious institutions. At times, however, grieving persons who do not have adequate social supports turn to the clinician as an outlet for their grief. Crying is an integral part of the grieving process and should be encouraged. Short-term supportive counseling that promotes ventilation of feelings is usually helpful.",
"   </p>",
"   <p>",
"    Sleep disruption is a common symptom of grief. Short-term prescription of a sleep hypnotic may be effective in promoting sleep. For individuals who experience high levels of anxiety, a time-limited prescription of an anxiolytic can be useful as a crisis measure. However, these medications generally should not be prescribed at high doses or for long periods since their use has the potential to retard and inhibit the grieving process.",
"   </p>",
"   <p>",
"    Support groups are a valuable resource for many bereaved individuals and have been shown to facilitate grief resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/27\">",
"     27",
"    </a>",
"    ]. Some support groups target particular types of deaths, such as death of a spouse, suicide, death of a child, AIDS, violent crime. However, a randomized trial of cognitive behavioral therapy for relatives of people who committed suicide did not reduce the risk for complicated grief, though may have had other beneficial effects related to blame and maladaptive grief reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local hospice organizations usually can identify community resources for bereavement support. Chaplains, social workers, and grief counselors also provide services to bereaved individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of complicated or prolonged grief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because complicated grief can lead to prolonged dysfunction, and is often difficult to differentiate from major depression, patients with complicated grief should be referred to a psychiatrist for evaluation. Treatment aims to facilitate understanding of the loss and its impact on the survivor's sense of self and sense of the future. Focus is also on mastering concrete tasks (eg, managing finances, learning how to cook) that were carried out by the deceased and that can lead to a new sense of competence and independence. Encouragement to develop new routines, new relationships, and to practice good self-care (diet, exercise, sleep, etc) is also helpful. Support groups can be an important resource for the bereaved by reducing the sense of isolation, supporting the development of new relationships, and teaching concrete survival strategies.",
"   </p>",
"   <p>",
"    Effective treatments for complicated grief are beginning to emerge. Complicated grief treatment (CGT) is a psychotherapeutic approach that includes cognitive behavioral methods similar to those used for post-traumatic stress disorder (ie, confronting the loss through exposure). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .) A randomized trial in 95 people with complicated grief found a higher response with CGT than with interpersonal psychotherapy (51 versus 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/29\">",
"     29",
"    </a>",
"    ]. Other studies have shown reductions in grief symptoms with crisis intervention, brief dynamic psychotherapy, and support groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/25\">",
"     25",
"    </a>",
"    ]. An open-label trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    demonstrated a 53 percent reduction in symptoms of complicated grief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment of bereavement-related depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bereaved patients who have symptoms of depression for at least two weeks, six to eight weeks after a major loss, should be considered candidates for a therapeutic trial of antidepressants and psychotherapy. Major depression following a loss responds to the same therapeutic approach as major depression in general. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .) Treatment with antidepressants is associated with improvement in symptoms of depression, but appears to be ineffective in ameliorating the symptoms of grief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. One study, as an example, found that treatment of bereavement-related depression in 13 patients resulted in a 68 percent decrease in the Hamilton rating score for depression after a median treatment interval of 6.4 weeks; the intensity of grief did not change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31190/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal bereavement can manifest as intense symptoms that subside slowly but usually cause little impairment by six months (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal bereavement'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Complicated/prolonged",
"      </span>",
"      grief is the persistence for at least six months of yearning associated with four of eight symptoms: difficulty moving on, detachment, bitterness, feeling that life is empty, trouble accepting the death, feeling of meaningless with future, agitation, difficulty trusting others. We recommend psychiatric referral for these patients (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Complicated or prolonged grief'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of complicated or prolonged grief'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The diagnosis of major depression in the grieving individual is difficult. Patients with symptoms of bereavement-related depression for at least two weeks, six to eight weeks after a major loss, should be treated for depression (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Bereavement related depression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment of bereavement-related depression'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinicians can help ameliorate grief reactions in relatives of their dying patients. They should be alert to risk factors for abnormal grieving. Immediate communication, expression of condolence after death, and follow-up by phone or appointment within two weeks can be helpful. Clinicians should encourage the bereaved to maintain regular patterns of activity, sleep, exercise, and nutrition. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors for poor bereavement outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Caring for the bereaved after the death'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Committee on Care at the End of Life. Approaching death: Improving care at the end of life. Institute of Medicine, National Academy Press: Washington, DC, 1997.",
"    </li>",
"    <li>",
"     Osterweis, M, et al. Bereavement: Reactions, Consequences, and Care. National Academy Press, Washington, DC 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/3\">",
"      Prigerson, HG. Complicated grief: when the path of adjustment leads to a dead end. Bereavement Care 2004; 23:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/4\">",
"      Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res 1967; 11:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/5\">",
"      Lindemann, E. Symptomatology and management of acute grief. Am J Psychiatry 1944; 101:141.",
"     </a>",
"    </li>",
"    <li>",
"     Kubler Ross, E. On Death and Dying. Macmillan Publishing Company, New York 1969.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/7\">",
"      Maciejewski PK, Zhang B, Block SD, Prigerson HG. An empirical examination of the stage theory of grief. JAMA 2007; 297:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/8\">",
"      Ness DE, Pfeffer CR. Sequelae of bereavement resulting from suicide. Am J Psychiatry 1990; 147:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/9\">",
"      Zisook S, Shuchter SR. Depression through the first year after the death of a spouse. Am J Psychiatry 1991; 148:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/10\">",
"      Stroebe M, Schut H, Stroebe W. Health outcomes of bereavement. Lancet 2007; 370:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/11\">",
"      Prigerson HG, Shear MK, Frank E, et al. Traumatic grief: a case of loss-induced trauma. Am J Psychiatry 1997; 154:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/12\">",
"      van Doorn C, Kasl SV, Beery LC, et al. The influence of marital quality and attachment styles on traumatic grief and depressive symptoms. J Nerv Ment Dis 1998; 186:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/13\">",
"      Chen JH, Bierhals AJ, Prigerson HG, et al. Gender differences in the effects of bereavement-related psychological distress in health outcomes. Psychol Med 1999; 29:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/14\">",
"      Prigerson HG, Bierhals AJ, Kasl SV, et al. Traumatic grief as a risk factor for mental and physical morbidity. Am J Psychiatry 1997; 154:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/15\">",
"      Kim K, Jacobs S. Pathologic grief and its relationship to other psychiatric disorders. J Affect Disord 1991; 21:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/16\">",
"      Zisook S, Shuchter SR. Uncomplicated bereavement. J Clin Psychiatry 1993; 54:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/17\">",
"      Helsing KJ, Szklo M. Mortality after bereavement. Am J Epidemiol 1981; 114:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/18\">",
"      Parkes CM. The first year of bereavement. A longitudinal study of the reaction of London widows to the death of their husbands. Psychiatry 1970; 33:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/19\">",
"      Parkes CM, Brown RJ. Health after bereavement. A controlled study of young Boston widows and widowers. Psychosom Med 1972; 34:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/20\">",
"      Irwin M, Daniels M, Weiner H. Immune and neuroendocrine changes during bereavement. Psychiatr Clin North Am 1987; 10:449.",
"     </a>",
"    </li>",
"    <li>",
"     Parkes, CM, Weiss, RS. Recovery from bereavement. Basic Books, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/22\">",
"      Christakis NA, Iwashyna TJ. The health impact of health care on families: a matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. Soc Sci Med 2003; 57:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/23\">",
"      Bradley EH, Prigerson H, Carlson MD, et al. Depression among surviving caregivers: does length of hospice enrollment matter? Am J Psychiatry 2004; 161:2257.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd, Lippincott Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/25\">",
"      Prigerson HG, Jacobs SC. Perspectives on care at the close of life. Caring for bereaved patients: \"all the doctors just suddenly go\". JAMA 2001; 286:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/26\">",
"      Chen JH, Gill TM, Prigerson HG. Health behaviors associated with better quality of life for older bereaved persons. J Palliat Med 2005; 8:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/27\">",
"      Vachon ML, Lyall WA, Rogers J, et al. A controlled study of self-help intervention for widows. Am J Psychiatry 1980; 137:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/28\">",
"      de Groot M, de Keijser J, Neeleman J, et al. Cognitive behaviour therapy to prevent complicated grief among relatives and spouses bereaved by suicide: cluster randomised controlled trial. BMJ 2007; 334:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/29\">",
"      Shear K, Frank E, Houck PR, Reynolds CF 3rd. Treatment of complicated grief: a randomized controlled trial. JAMA 2005; 293:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/30\">",
"      Zygmont M, Prigerson HG, Houck PR, et al. A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. J Clin Psychiatry 1998; 59:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/31\">",
"      Jacobs SC, Nelson JC, Zisook S. Treating depressions of bereavement with antidepressants. A pilot study. Psychiatr Clin North Am 1987; 10:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31190/abstract/32\">",
"      Pasternak, RE, Reynolds, CR III, Schlernitzauer, M, et al. Acute open-trial nortriptyline therapy of bereavement-related depression in late life. J Clin Psychiatry 1991; 52:307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1724 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31190=[""].join("\n");
var outline_f30_29_31190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL BEREAVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anticipatory grief",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal grief reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Normal grief resolution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ABNORMAL BEREAVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors for poor bereavement outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Psychological sequelae of abnormal bereavement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Complicated or prolonged grief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bereavement related depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medical sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CARING FOR THE BEREAVED BEFORE THE DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARING FOR THE BEREAVED AFTER THE DEATH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of complicated or prolonged grief",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment of bereavement-related depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_29_31191="Arterial supply to the pancreas";
var content_f30_29_31191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Arterial supply to the pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Original illustration from: Woodburne RT. Essentials of Human Anatomy, New York: Oxford University Press, 1973. Copyright &copy; 1973.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31191=[""].join("\n");
var outline_f30_29_31191=null;
var title_f30_29_31192="Lung transplantation: Disease-based choice of procedure";
var content_f30_29_31192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lung transplantation: Disease-based choice of procedure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31192/contributors\">",
"     Ramsey R Hachem, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31192/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31192/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/29/31192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung and heart-lung transplantation have been performed for most end-stage lung diseases. The different lung transplant procedures, the most common diseases that require lung transplant, and how the underlying lung disease affects the choice of procedure will be reviewed here.",
"   </p>",
"   <p>",
"    An overview of lung transplantation, indications and organizational process, outcomes, international guidelines for recipient selection, and indications for lung transplantation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TYPES OF LUNG TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until 1989, combined heart-lung transplant (HLT) was the most common form of lung transplantation in the United States. Subsequently, single lung transplantation (SLT) became the most common procedure; however, the proportion of bilateral lung transplants (BLT) has now surpassed SLT (",
"    <a class=\"graphic graphic_figure graphicRef71574 \" href=\"mobipreview.htm?14/25/14736\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition to these procedures, split lung bilateral lobar transplants and living donor lobar lung transplants are occasionally performed. The reasons for choosing one procedure over another are reviewed here. An overview of the operative techniques is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the 2007 Registry report, the median survival for all adult recipients is five years, but bilateral lung recipients appear to have a better median survival than single lung recipients (5.9 versus 4.4 years, respectively) (For a figure showing updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled Number of Lung Transplants Performed by Year and Procedure Type at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is unclear if this survival advantage is directly related to the type of operation or to the underlying recipient characteristics.",
"   </p>",
"   <p>",
"    The general characteristics and",
"    <span class=\"nowrap\">",
"     advantages/disadvantages",
"    </span>",
"    of the different types of lung transplantation are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bilateral lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously discussed, there are limited data suggesting that BLT may be associated with improved long-term survival compared with SLT. In addition, BLT may allow greater use of marginal donor lungs that would otherwise be declined for single lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Single lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with bilateral lung transplantation, SLT extends the limited supply of donor organs to more patients. However, it provides less lung function as a buffer for late complications. As the operative procedure is shorter than bilateral transplantation, SLT may be preferable in older patients or those who would not tolerate the longer anesthesia time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Split lung bilateral lobar transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal advantage of split lung bilateral lobar transplantation is that it permits single lung transplantation from a donor with a large size discrepancy with the recipient, such as a small adult or child. With this procedure, a single left lung from a donor who is approximately 15 percent taller than the recipient is divided such that the left upper and lower lobes are implanted into the recipient's right and left hemithorax, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. When appropriate, the remaining donor lung is given to another recipient. However, technical difficulties and appropriate donor-recipient size matching have limited the use of this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Living donor lobar lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with kidney and liver transplantation, living donor lobar lung transplantation was developed to increase organ availability and reduce long waiting times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This procedure requires lung tissue from two donors. The right lower lobe harvested from one donor is implanted into the recipient's right hemithorax, while the left lower lobe from another donor is placed in the recipient's left hemithorax. Because only one lobe is implanted in each hemithorax, this operation is limited to children and adults with small stature. As a result, the number of living donor lobar lung transplants performed annually peaked at 29 in 1999 in the US and has diminished rapidly since the implementation of the current lung allocation system, which accounts for medical urgency. In fact, no living donor lobar transplants were performed in the United States in 2008 and only one was performed in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in countries where brain death is not recognized, this remains the only viable lung transplant procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heart-lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart-lung transplantation is reserved for patients with irreversible heart disease that may occur in conjunction with end-stage lung disease. However, the ability to predict whether heart function can recover after lung transplantation alone can be difficult. Severe right ventricular dysfunction, for example, has reversed after isolated lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Therefore, lung transplantation alone can be performed even in the setting of severe right heart failure, unless there is also left ventricular failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DISEASE-BASED CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying lung disease is an important factor in deciding which lung transplant procedure to perform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) is the most common indication for lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ]. The specific indications for lung transplantation in COPD are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link&amp;anchor=H24#H24\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Supplemental therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two principal transplant options for those with end-stage COPD are SLT and BLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/4,16-21\">",
"     4,16-21",
"    </a>",
"    ]. The choice between these options is center specific, but there is a growing trend in favor of BLT. In an analysis of 2006 data from the International Society for Heart and Lung Transplantation (ISHLT) Registry, 56 percent of patients with COPD received a BLT and 44 percent a SLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ]. By comparison, 80 percent of transplants for COPD in 1993 were SLT. In a separate analysis, among patients with emphysema due to alpha-1 antitrypsin deficiency 50 percent received an SLT and 50 percent a BLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A factor favoring the bilateral procedure is the slightly superior actuarial survival in BLT recipients with COPD (",
"    <a class=\"graphic graphic_figure graphicRef55546 \" href=\"mobipreview.htm?38/14/39149\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This trend toward improved long-term survival following bilateral transplantation is primarily seen in patients under age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. A retrospective analysis of 9883 recipients with COPD demonstrated that, among those younger than 60, bilateral transplantation offered a survival advantage over single lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, among those older than 60, the survival benefit of bilateral transplantation over single was no longer apparent. A possible explanation for this is that SLT is a simpler, shorter operation with a lower perioperative complication rate than BLT in older patients with emphysema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a few additional differences between SLT and BLT that may account for the survival benefits observed with BLT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following SLT, a few patients develop severe hyperinflation of the remaining native lung such that it crosses the mediastinum and compresses the transplanted lung. When this occurs, lung volume reduction surgery of the native lung is sometimes needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The leading cause of death among lung transplant recipients over the long term is chronic rejection. Among those who develop this complication, BLT recipients survive longer than patients who have received a SLT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/22,27\">",
"       22,27",
"      </a>",
"      ]. BLT provides additional lung reserve that may compensate for the loss of lung function resulting from chronic rejection, although the mechanism underlying this observation is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, SLT may be associated with an increased risk of chronic rejection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link\">",
"       \"Lung transplantation: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=see_link\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary function testing provides an indirect measure of quality of life after the different lung transplant procedures. Among patients with COPD who undergo lung transplantation, both BLT and SLT result in an improvement in spirometry; however, the change in exercise capacity is less dramatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/16,29,30\">",
"     16,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17194?source=see_link&amp;anchor=H17#H17\">",
"     \"Physiologic changes following lung transplantation\", section on 'COPD/emphysema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, cystic fibrosis (CF) is the foremost cause of end-stage obstructive lung disease during the first three decades of life; it is the third most common indication for lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The indications for lung transplantation in cystic fibrosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H26#H26\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Lung transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral lung transplantation is the procedure of choice for most adults with CF; heart-lung transplantation is a rarely needed alternative for those patients with concomitant left heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Because of the risk of spillover infection, removal of both lungs is mandatory for lung transplantation for CF and is generally advised for other forms of generalized bronchiectasis although data are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Living donor lobar lung transplantation (LDLT) is an alternative that circumvents the shortage of deceased donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This approach is rarely needed now that waiting list times have decreased with the Lung Allocation System. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link&amp;anchor=H7#H7\">",
"     \"Lung transplantation: An overview\", section on 'Lung allocation'",
"    </a>",
"    .) LDLT is especially suited for children and young adults with CF who are small in size and would attain sufficient lung function from two adult donor lobes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/38\">",
"     38",
"    </a>",
"    ]. Long-term survival results with this procedure have been comparable to transplantation from deceased donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/39\">",
"     39",
"    </a>",
"    ]. Additionally, donor lobectomy has been associated with relatively low morbidity and no mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single lung transplantation with a contralateral pneumonectomy has been employed in few special circumstances, but this has not been the standard approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Lung transplantation has been successfully combined with simultaneous liver transplantation in a few patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Idiopathic interstitial pneumonias",
"    </span>",
"    &nbsp;&mdash;&nbsp;End-stage lung disease from the idiopathic interstitial pneumonias accounts for about 20 percent of lung transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2,44\">",
"     2,44",
"    </a>",
"    ]. Among these, idiopathic pulmonary fibrosis (IPF) most commonly requires lung transplantation; nonspecific interstitial pneumonitis (NSIP) is the next most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Discussions of the indications for and timing of transplant for IPF and NSIP are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of idiopathic pulmonary fibrosis\", section on 'Transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=see_link&amp;anchor=H23#H23\">",
"     \"Nonspecific interstitial pneumonia\", section on 'Lung transplant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Single lung transplantation was the standard procedure for patients with IPF for many years and survival statistics were comparable to other indications for lung transplantation (",
"    <a class=\"graphic graphic_figure graphicRef57297 \" href=\"mobipreview.htm?38/5/38992\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. However, a growing percentage of patients are now undergoing BLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2,52\">",
"     2,52",
"    </a>",
"    ]. For example, over 45 percent of those transplanted in 2005 underwent BLT. In contrast, only 15 percent of patients with IPF underwent BLT and 85 percent underwent SLT in 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ]. The reasons for this shift in practice are unclear, although improved surgical technique, as well as better lung function and longer survival for BLT recipients are likely contributors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival advantage of BLT over SLT is best described in the 2007 ISHLT Registry Report that included all transplants for IPF between 1990 and 2005 (n = 3362) (",
"    <a class=\"graphic graphic_figure graphicRef64204 \" href=\"mobipreview.htm?26/50/27438\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ]. Of note, the survival advantage for BLT is not evident until three or more years after transplantation. In an analysis of the UNOS registry that included 3327 patients with IPF, BLT was associated with a longer median survival than SLT (5.2 versus 3.8 years, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/53\">",
"     53",
"    </a>",
"    ]. However, after adjusting for recipient and donor baseline characteristics, the two procedures had a similar survival rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/52\">",
"     52",
"    </a>",
"    ]. This is in contrast to a previous report of a survival advantage for SLT over BLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite superior survival with BLT, the limited availability of lungs for transplantation makes it more difficult to obtain a BLT than SLT. Among 1339 patients with IPF listed for lung transplantation between May 2005 and June 2009, those listed for BLT only, compared with SLT only or either SLT or BLT, were slightly more likely to die on the waiting list and less likely to receive a transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, the choice of procedure requires careful consideration of the patient&rsquo;s anticipated survival pre and post transplant.",
"   </p>",
"   <p>",
"    Patients with nonspecific interstitial pneumonia (NSIP) generally have a better prognosis and better response to medical therapy than those with IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Nonetheless, some patients with NSIP, especially those with the fibrotic variant, have a progressive decline in lung function, and eventually become candidates for transplantation. The choice between SLT and BLT for NSIP follows the experience with IPF described above.",
"   </p>",
"   <p>",
"    Living donor lobar lung transplantation has been suggested as an alternative procedure for patients with end-stage IPF who are not expected to survive the waiting time for deceased donor transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/55\">",
"     55",
"    </a>",
"    ]. However, experience with the current UNOS lung organ allocation system suggests that the waiting time for a deceased donor lung for a patient with end-stage IPF should be short and that living donor transplantation is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary arterial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary arterial hypertension (PAH) accounts for less than 5 percent of lung transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2,56\">",
"     2,56",
"    </a>",
"    ]. Overall, patients with PAH have the highest 30 day mortality following lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ]. The specific indications for lung transplantation in PAH are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link&amp;anchor=H34#H34\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both single and bilateral lung transplantation have been performed successfully for PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2,57\">",
"     2,57",
"    </a>",
"    ]. Based on analysis of outcomes databases, survival comparisons have generally favored BLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2,10,22,56,58-60\">",
"     2,10,22,56,58-60",
"    </a>",
"    ]. In the ISHLT registry, there is a trend towards a survival benefit from BLT, but it does not achieve statistical significance (",
"    <a class=\"graphic graphic_figure graphicRef75206 \" href=\"mobipreview.htm?30/10/30894\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional factor that has favored BLT is that SLT for PAH is a difficult procedure. Ventilation is evenly divided between the allograft and the native lung while perfusion is almost entirely directed to the allograft (due to the high pulmonary vascular resistance in the native lung). Any complication in the allograft (eg, pneumonia, primary graft dysfunction, rejection) can result in severe ventilation-perfusion mismatch and hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/61\">",
"     61",
"    </a>",
"    ]. It is unclear why survival statistics do not clearly favor BLT over SLT, given this perioperative disadvantage of SLT.",
"   </p>",
"   <p>",
"    Heart-lung transplantation was originally the standard procedure for patients with PAH. However, it was replaced by isolated lung transplantation in most centers in the 1990s. This is because right ventricular dysfunction recovers quickly with the rapid reduction in pulmonary vascular resistance after lung transplantation, making heart transplantation unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/58,62,63\">",
"     58,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Eisenmenger's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eisenmenger's syndrome may result from atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), or multiple cardiac anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/64\">",
"     64",
"    </a>",
"    ]. Both heart-lung transplantation and lung transplantation with intracardiac repair are performed for patients with Eisenmenger's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/64\">",
"     64",
"    </a>",
"    ]. Indications for transplantation are discussed separately. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/24,64-67\">",
"     24,64-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link&amp;anchor=H20#H20\">",
"     \"Medical management of Eisenmenger syndrome\", section on 'Transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal therapeutic choice in those with Eisenmenger's syndrome is based principally upon the underlying heart disorder. Data in support of specific options are derived entirely from retrospective reviews of relatively small numbers of patients. In one of the larger retrospective reviews, the outcomes after lung and heart-lung transplantation were reported for 605 patients with Eisenmenger's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/64\">",
"     64",
"    </a>",
"    ]. Causes of the syndrome included ASD (171 patients), VSD (164), multiple congenital anomalies (68) and PDA (32). Procedures included HLT, BLT, and SLT in 430, 106 and 69 transplants, respectively. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those with VSD, there was improved survival following HLT compared with BLT and SLT. This seemed related to early postoperative ventricular failure in the lung transplant group.",
"     </li>",
"     <li>",
"      Survival following BLT or SLT for ASD or PDA is not as good as HLT for VSD or multiple cardiac anomalies. This suggests some technical difficulties arise when",
"      <span class=\"nowrap\">",
"       BLT/SLT",
"      </span>",
"      are combined with cardiac repair, compared with the relatively more simple procedure of HLT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on survival statistics, we suggest HLT in patients with Eisenmenger's syndrome due to VSD or other anomalies that are combined with severe left ventricular failure, when they meet criteria for transplantation.",
"   </p>",
"   <p>",
"    In patients with cardiac anomalies that can be surgically repaired (eg, ASD, PDA), the scarcity of heart-lung blocks makes it preferable to combine lung transplantation with intraoperative cardiac repair, unless the combined procedure would require prolonged time on cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/68\">",
"     68",
"    </a>",
"    ]. If the cardiac repair is more complicated than ASD or PDA repair, HLT is generally preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Secondary pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end-stage lung disease often develop secondary pulmonary hypertension (SPH). Heart-lung transplant is generally not needed unless both left and right heart failure are present. Data are conflicting as to whether SPH should affect the choice of SLT versus BLT. In a retrospective review that compared outcomes among 104 patients with normal mean pulmonary artery pressure (PAM), mildly elevated PAM and high PAM, no differences in survival were noted between types of procedure (SLT or BLT) or between levels of PAM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/67\">",
"     67",
"    </a>",
"    ]. In contrast, among patients undergoing transplant for idiopathic pulmonary fibrosis, SPH was an independent risk factor for early mortality after single lung transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31192/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral lung transplantation (BLT) is now the most common lung transplant procedure, followed by single lung transplantation (SLT) (",
"      <a class=\"graphic graphic_figure graphicRef71574 \" href=\"mobipreview.htm?14/25/14736\">",
"       figure 1",
"      </a>",
"      ). In contrast, heart-lung transplantation has become an uncommon procedure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of types of lung transplant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, BLT is necessary only for bronchiectasis (eg, cystic fibrosis), but it is often performed for other indications because of the perceived better long-term outcomes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bilateral lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SLT extends the limited supply of donor organs to more patients, but it provides less lung function as a buffer for late complications than BLT and may not be appropriate when using marginal organ donors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Single lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Living lobar lung transplantation in which each of two donors provides a lobe was developed to increase organ availability and reduce long waiting times, but this has become an uncommon procedure in recent years because of changes in the allocation system. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Living donor lobar lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both SLT and BLT are performed for COPD and alpha-1 antitrypsin deficiency. A trend toward improved long-term survival following BLT is primarily seen in patients under the age of 60. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic obstructive pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic pulmonary fibrosis is the most common idiopathic interstitial pneumonia that requires lung transplantation. SLT appears to provide equal survival to BLT, at least for the first three years post transplant. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Idiopathic interstitial pneumonias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Removal of both lungs is mandatory in lung transplantation for patients with end-stage cystic fibrosis, because of the risk of spillover infection. Therefore, BLT is the preferred procedure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cystic fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pulmonary arterial hypertension (PAH) who require lung transplantation, we favor BLT over SLT if organ availability is adequate. A few patients with concomitant left heart failure will need HLT. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulmonary arterial hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heart-lung transplantation should be reserved for patients with concomitant lung and heart disease who cannot be treated by lung transplantation alone (eg, Eisenmenger's in a patient with a surgically uncorrectable cardiac anomaly). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Heart-lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/1\">",
"      Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/2\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant 2011; 30:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/3\">",
"      Sundaresan S, Semenkovich J, Ochoa L, et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995; 109:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/4\">",
"      Low DE, Trulock EP, Kaiser LR, et al. Morbidity, mortality, and early results of single versus bilateral lung transplantation for emphysema. J Thorac Cardiovasc Surg 1992; 103:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/5\">",
"      Couetil JP, Tolan MJ, Loulmet DF, et al. Pulmonary bipartitioning and lobar transplantation: a new approach to donor organ shortage. J Thorac Cardiovasc Surg 1997; 113:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/6\">",
"      Artemiou O, Birsan T, Taghavi S, et al. Bilateral lobar transplantation with the split lung technique. J Thorac Cardiovasc Surg 1999; 118:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/7\">",
"      Starnes VA, Barr ML, Cohen RG. Lobar transplantation. Indications, technique, and outcome. J Thorac Cardiovasc Surg 1994; 108:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/8\">",
"      Starnes VA, Barr ML, Cohen RG, et al. Living-donor lobar lung transplantation experience: intermediate results. J Thorac Cardiovasc Surg 1996; 112:1284.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/latestData/rptData.asp (Accessed on March 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/10\">",
"      Pasque MK, Trulock EP, Kaiser LR, Cooper JD. Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up. Circulation 1991; 84:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/11\">",
"      Ritchie M, Waggoner AD, D&aacute;vila-Rom&aacute;n VG, et al. Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantation. J Am Coll Cardiol 1993; 22:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/12\">",
"      Kramer MR, Valantine HA, Marshall SE, et al. Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Am J Cardiol 1994; 73:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/13\">",
"      Bando K, Armitage JM, Paradis IL, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994; 108:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/14\">",
"      Pasque MK, Trulock EP, Cooper JD, et al. Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. Circulation 1995; 92:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/15\">",
"      Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest 2005; 127:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/16\">",
"      Patterson GA, Maurer JR, Williams TJ, et al. Comparison of outcomes of double and single lung transplantation for obstructive lung disease. The Toronto Lung Transplant Group. J Thorac Cardiovasc Surg 1991; 101:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/17\">",
"      Mal H, Sleiman C, Jebrak G, et al. Functional results of single-lung transplantation for chronic obstructive lung disease. Am J Respir Crit Care Med 1994; 149:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/18\">",
"      Levine SM, Anzueto A, Peters JI, et al. Medium term functional results of single-lung transplantation for endstage obstructive lung disease. Am J Respir Crit Care Med 1994; 150:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/19\">",
"      Brunsting LA, Lupinetti FM, Cascade PN, et al. Pulmonary function in single lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1994; 107:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/20\">",
"      Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/21\">",
"      Sundaresan RS, Shiraishi Y, Trulock EP, et al. Single or bilateral lung transplantation for emphysema? J Thorac Cardiovasc Surg 1996; 112:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/22\">",
"      Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/23\">",
"      Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence of recipient age on survival and secondary end-points. J Heart Lung Transplant 2001; 20:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/24\">",
"      Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 2008; 371:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/25\">",
"      Thabut G, Ravaud P, Christie JD, et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/26\">",
"      Schulman LL, O'Hair DP, Cantu E, et al. Salvage by volume reduction of chronic allograft rejection in emphysema. J Heart Lung Transplant 1999; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/27\">",
"      Hadjiliadis D, Chaparro C, Gutierrez C, et al. Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease. Am J Transplant 2006; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/28\">",
"      Mason DP, Rajeswaran J, Murthy SC, et al. Spirometry after transplantation: how much better are two lungs than one? Ann Thorac Surg 2008; 85:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/29\">",
"      Levy RD, Ernst P, Levine SM, et al. Exercise performance after lung transplantation. J Heart Lung Transplant 1993; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/30\">",
"      Pochettino A, Kotloff RM, Rosengard BR, et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease: intermediate-term results. Ann Thorac Surg 2000; 70:1813.",
"     </a>",
"    </li>",
"    <li>",
"     Cystic Fibrosis Foundation. Patient Registry 1995 Annual Data Report. Cystic Fibrosis Foundation. Bethesda, MD, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/32\">",
"      Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/33\">",
"      de Leval MR, Smyth R, Whitehead B, et al. Heart and lung transplantation for terminal cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 1991; 101:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/34\">",
"      Ganesh JS, Rogers CA, Bonser RS, et al. Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study. Eur Respir J 2005; 25:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/35\">",
"      Vricella LA, Karamichalis JM, Ahmad S, et al. Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience. Ann Thorac Surg 2002; 74:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/36\">",
"      Egan TM, Detterbeck FC, Mill MR, et al. Improved results of lung transplantation for patients with cystic fibrosis. J Thorac Cardiovasc Surg 1995; 109:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/37\">",
"      Yankaskas JR, Mallory GB Jr. Lung transplantation in cystic fibrosis: consensus conference statement. Chest 1998; 113:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/38\">",
"      Bowdish ME, Pessotto R, Barbers RG, et al. Long-term pulmonary function after living-donor lobar lung transplantation in adults. Ann Thorac Surg 2005; 79:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/39\">",
"      Barr ML, Schenkel FA, Bowdish ME, Starnes VA. Living donor lobar lung transplantation: current status and future directions. Transplant Proc 2005; 37:3983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/40\">",
"      Bowdish ME, Barr ML, Schenkel FA, et al. A decade of living lobar lung transplantation: perioperative complications after 253 donor lobectomies. Am J Transplant 2004; 4:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/41\">",
"      Piotrowski JA, Splittgerber FH, Donovan TJ, et al. Single-lung transplantation in a patient with cystic fibrosis and an asymmetric thorax. Ann Thorac Surg 1997; 64:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/42\">",
"      Forty J, Hasan A, Gould FK, et al. Single lung transplantation with simultaneous contralateral pneumonectomy for cystic fibrosis. J Heart Lung Transplant 1994; 13:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/43\">",
"      Couetil JP, Houssin DP, Soubrane O, et al. Combined lung and liver transplantation in patients with cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 1995; 110:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/44\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/45\">",
"      Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/46\">",
"      Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/47\">",
"      Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/48\">",
"      Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/49\">",
"      Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986; 314:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/50\">",
"      Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 2000; 120:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/51\">",
"      Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005; 79:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/52\">",
"      Weiss ES, Allen JG, Merlo CA, et al. Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann Thorac Surg 2009; 88:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/53\">",
"      Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 2009; 151:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/54\">",
"      Nathan SD, Shlobin OA, Ahmad S, et al. Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. J Heart Lung Transplant 2010; 29:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/55\">",
"      Date H, Tanimoto Y, Goto K, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chest 2005; 128:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/56\">",
"      Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:63S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/57\">",
"      Goldstein BS, Sweet SC, Mao J, et al. Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience. J Heart Lung Transplant 2011; 30:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/58\">",
"      Levine SM, Gibbons WJ, Bryan CL, et al. Single lung transplantation for primary pulmonary hypertension. Chest 1990; 98:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/59\">",
"      Gammie JS, Keenan RJ, Pham SM, et al. Single- versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1998; 115:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/60\">",
"      Mendeloff EN, Meyers BF, Sundt TM, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 2002; 73:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/61\">",
"      Levine SM, Jenkinson SG, Bryan CL, et al. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension. Chest 1992; 101:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/62\">",
"      Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/63\">",
"      Chapelier A, Vouh&eacute; P, Macchiarini P, et al. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1993; 106:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/64\">",
"      Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/65\">",
"      Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/66\">",
"      Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002; 21:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/67\">",
"      Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31192/abstract/68\">",
"      Aokage K, Date H, Okazaki M, et al. Living-donor lobar lung transplantation and closure of atrial septal defect for adult Eisenmenger's syndrome. J Heart Lung Transplant 2009; 28:1107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4660 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31192=[""].join("\n");
var outline_f30_29_31192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF TYPES OF LUNG TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bilateral lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Single lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Split lung bilateral lobar transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Living donor lobar lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DISEASE-BASED CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Idiopathic interstitial pneumonias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary arterial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Eisenmenger's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Secondary pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4660|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/25/14736\" title=\"figure 1\">",
"      Lung transplant procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/14/39149\" title=\"figure 2\">",
"      Survival after transplant COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/5/38992\" title=\"figure 3\">",
"      Survival by diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/50/27438\" title=\"figure 4\">",
"      Survival after transplant IPF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/10/30894\" title=\"figure 5\">",
"      Survival after transplant PAH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/99?source=related_link\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=related_link\">",
"      Lung transplantation: Donor lung preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17194?source=related_link\">",
"      Physiologic changes following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_29_31193="Vitamin D and extraskeletal health";
var content_f30_29_31193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vitamin D and extraskeletal health",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31193/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31193/contributors\">",
"     Roger Bouillon, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31193/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31193/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/29/31193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H651633\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency was originally discovered as the cause of rickets due to lack of exposure to sunshine or vitamin D rich food. This disease is still endemic in major parts of the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, several meta-analyses showed that supplementation with vitamin D and calcium decreased the risk of osteoporotic fractures in the elderly. The details of the protocols and overall results of the studies are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H2#H2\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its role in calcium and bone homeostasis, vitamin D potentially regulates many other cellular functions. The vitamin D receptor (VDR) is nearly universally expressed in nucleated cells. About 3 percent of the",
"    <span class=\"nowrap\">",
"     human/mouse",
"    </span>",
"    genome is under the control of 1,25-dihydroxyvitamin D, the active form of vitamin D. Furthermore, at least 10 tissues outside the kidney express 1&alpha;-hydroxylase (CYP27B1), the enzyme responsible for converting vitamin D to its active form, and therefore the active hormone can be generated in an auto or paracrine way. Thus, the spectrum of activity of the vitamin D endocrine system is much broader than",
"    <span class=\"nowrap\">",
"     calcium/bone",
"    </span>",
"    homeostasis, and in this regard, the vitamin D-VDR system resembles that of other ligands of nuclear receptors, such as thyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This chapter will review the &ldquo;extraskeletal&rdquo; effects of vitamin D (deficiency), especially its effect on muscle function, cancer, and on the immune, cardiovascular, and metabolic system. The skeletal manifestations, causes, and treatment of vitamin D deficiency are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H2#H2\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651640\">",
"    <span class=\"h1\">",
"     MUSCLE FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651647\">",
"    <span class=\"h2\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several lines of evidence that suggest a relationship between vitamin D and muscle function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/5\">",
"     5",
"    </a>",
"    ]. Muscle from vitamin D receptor (VDR) null mice show clear developmental abnormalities as immature muscle genes and proteins survive in VDR null but not wild type adult muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, striated muscle fibers are smaller in VDR null mice. VDR is also expressed in human muscle tissue. Children with hereditary vitamin D deficiency (ie, genetic CYP27B1 deficiency) who are deficient in the production of 1,25-dihydroxyvitamin D have profound muscle weakness, which vitamin D or 1,25-dihydroxyvitamin D therapy rapidly improves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies also show a relationship between nutritionally poor 25-hydroxyvitamin D (25OHD) status and muscle weakness in children and elderly subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. In most studies, the lowest vitamin D concentrations (&lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;50",
"    <span class=\"nowrap\">",
"     nmol/L]",
"    </span>",
"    and especially &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;25",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    were associated with the poorest muscle function, whereas higher levels of 25OHD (&gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&gt;50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    were associated with better muscle function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of eight observational and eight interventional studies examining the effects of low serum vitamin D concentration and vitamin D supplementation on muscle, balance, and gait in elderly persons 65 years and older found mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/11\">",
"     11",
"    </a>",
"    ]. Five of the eight observational studies showed a significant positive association between serum 25OHD concentration and physical performance. However, the majority of interventional trials (six of eight) did not show a significant effect of vitamin D supplementation on balance or gait. Four of the trials showed a significant effect on muscle strength. Few studies used proximal muscle strength (the most affected muscle function in clinical case reports) as a true endpoint and no studies provided vitamin D supplementation in doses higher than 2000 international units (Units) per day.",
"   </p>",
"   <p>",
"    In a subsequent randomized trial (not included in the systematic review), 302 elderly women (mean age 77 years) were randomly assigned to vitamin D2 (1000 units) or placebo daily for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/12\">",
"     12",
"    </a>",
"    ]. All patients received 1000 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    daily in divided doses. At baseline, mean serum 25OHD concentration was 17.7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (43",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    There was a significant improvement in mobility (timed up and go test) and lower limb muscle strength (including all measures of hip strength) in both groups with no between group difference. Thus, a causal relationship between vitamin D supplementation and improvement in muscle weakness has not been demonstrated in randomized trials and the optimal 25OHD concentration for muscle function is unknown. Any benefit of vitamin D supplementation on muscle strength is likely to occur in patients with baseline 25OHD levels below 10 or 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25 or 50",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651654\">",
"    <span class=\"h2\">",
"     Falls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few data demonstrating improvement in muscle weakness after vitamin D repletion in patients with nutritionally poor vitamin D status, there are several meta-analyses showing a reduction in risk of falls (relative risk reduction as high as 20 percent) following vitamin D supplementation, particularly when the baseline vitamin D status is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. Supplementation with doses ranging from 700 to 1000",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    was effective. In one meta-analysis, multicomponent group exercise and Tai Chi were even more effective in reducing risk of falls than vitamin D supplementation (RRs 0.65 and 0.83 versus 0.96). These trials are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\", section on 'Vitamin D supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A combined approach (vitamin D, calcium, exercise and general interventions) may provide additional advantage for the very elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651662\">",
"    <span class=\"h1\">",
"     CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1930s and 1940s it was observed that people living at higher latitudes were at higher risk of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/19\">",
"     19",
"    </a>",
"    ]. Subsequently, living at a higher latitude was linked to UV-B exposure and this observation introduced the possible link with vitamin D status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/20\">",
"     20",
"    </a>",
"    ]. There is now a very extensive literature on vitamin D, cell proliferation, and cancer. In vitro studies have shown that the active hormone or its analogues can decrease cell proliferation, and a very large number of genes are coherently activated or inactivated to generate this effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/4,21\">",
"     4,21",
"    </a>",
"    ]. In animal studies, deficiency of the vitamin D receptor (VDR) predisposes to precancerous lesions of the breast or intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies in humans (cross sectional studies and especially long-term prospective studies) revealed a link between poor vitamin D status (either evaluated by serum 25OHD or a surrogate estimation) and the risk of nearly all cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], but a re-analysis by a World Health Organization (WHO) working group identified colon cancer as the greatest risk associated with poor vitamin D status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/25\">",
"     25",
"    </a>",
"    ]. This finding was supported by the results of a meta-analysis of nine case-control studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/26\">",
"     26",
"    </a>",
"    ]. For each 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    increase in pre-diagnosis serum 25OHD concentration, there was a 6 percent (95% CI 3 to 9 percent) reduction in colorectal cancer risk. In one of the largest studies in the meta-analysis, a nested case-control study in European populations (2496 cases and controls), serum 25OHD levels between 10 and 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25 to 50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    compared with 20 to 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50 to 75",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were associated with a higher incidence of colorectal cancer (incidence rate ratio 1.28, 95% CI 1.05-1.56) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these results, a prospective case control study did not show a significant association between vitamin D status and colon or colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/28\">",
"     28",
"    </a>",
"    ]. Furthermore, some observational studies have shown an elevated risk of some cancers (eg, pancreatic) at higher 25OHD levels (RR 2.12, 95% CI 1.23-3.64 for levels &ge;40 versus 20 to 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&ge;100 versus 50 to 75",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of vitamin D intervention trials on cancer risk are inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/26\">",
"     26",
"    </a>",
"    ]. In the Women&rsquo;s Health Initiative (WHI), treatment with vitamin D3 (400",
"    <span class=\"nowrap\">",
"     Units/day)",
"    </span>",
"    and calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    did not have an effect on the incidence of colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/33\">",
"     33",
"    </a>",
"    ]. However, in a much smaller trial of vitamin D3 (1100",
"    <span class=\"nowrap\">",
"     Units/day)",
"    </span>",
"    and calcium (1400 to 1500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    supplementation, there was a significant decrease in overall cancer risk, but the number of events was small and calcium alone was nearly as efficient as calcium plus vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/34\">",
"     34",
"    </a>",
"    ]. In other vitamin D supplementation studies, in which the primary endpoint was fracture risk, there were no beneficial effects on cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, although some data suggest an association between vitamin D deficiency and cancer, the direction of the association may depend upon the serum 25OHD concentration. The current evidence is insufficient to support large dose vitamin D supplementation for cancer prevention or treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651669\">",
"    <span class=\"h1\">",
"     IMMUNE SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D has major effects on nearly all cells of the immune system. Antigen presenting cells, such as dendritic cells, macrophages, and T and B cells, express the vitamin D receptor (VDR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14670995\">",
"    <span class=\"h2\">",
"     Acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;The active form of vitamin D, 1,25-dihydroxyvitamin D, is an inhibitor of dendritic cell maturation and functions as an immune modulator, reducing activation of the acquired immune system. Therefore, vitamin D deficiency could theoretically increase the risk of autoimmune diseases, which has been reported in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies in humans suggest an association between vitamin D deficiency and type 1 diabetes (T1D), multiple sclerosis (MS), and inflammatory bowel disease. The strongest data exist for type 1 diabetes as several studies, mainly case-control studies, indicate that vitamin D supplementation in early infancy reduced the subsequent risk of T1D by about 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Vitamin D supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a large prospective case-control study involving over seven million US military personnel, Caucasian recruits with 25OHD levels below 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    had approximately a twofold increased risk for later development of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there are no randomized trials that have confirmed the efficacy or safety of vitamin D supplementation in preventing autoimmune disease. Until such data are available, vitamin D is not recommended for this purpose.",
"   </p>",
"   <p>",
"    There are conflicting reports on the association between vitamin D status and allergic diseases. In some reports, vitamin D deficiency (in pregnant women, children, or adolescents) has been associated with increased as well as with decreased frequency of allergic diseases such as asthma or eczema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/4,41,42\">",
"     4,41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20682?source=see_link&amp;anchor=H28#H28\">",
"     \"Risk factors for asthma\", section on 'Maternal diet during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14671002\">",
"    <span class=\"h2\">",
"     Innate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although vitamin D reduces activation of the acquired immune system, it activates the innate immune system, particularly monocytes and macrophages. Exposure of monocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    macrophages to bacterial infections upregulates VDR and 1&alpha;-hydroxylase expression, and after 48 hours, increases the production of several natural defensins (at least in human monocytes) capable of decreasing the intracellular survival of such mycobacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/2,43\">",
"     2,43",
"    </a>",
"    ]. Therefore, it is not unexpected that vitamin D deficiency is historically associated with infections. As an example, there is an association between vitamin D deficiency and tuberculosis and a putative beneficial (historic) effect of UVB exposure of such patients before antibiotic therapy became available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/44\">",
"     44",
"    </a>",
"    ]. A small-scale intervention study in India showed that vitamin D supplementation accelerated sputum clearance in patients with TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/45\">",
"     45",
"    </a>",
"    ]. In contrast, supplementation with vitamin D compared with placebo did not improve clinical outcomes (including mortality) among 281 West African patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/46\">",
"     46",
"    </a>",
"    ] or among 146 patients from London [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/47\">",
"     47",
"    </a>",
"    ], who had active TB and were receiving antituberculosis treatment. In the latter trial, patients with a mean baseline 25-hydroxyvitamin D level of 8.4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (21",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were randomly assigned to vitamin D (100,000 units [2.5 mg] every two weeks for two months) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/47\">",
"     47",
"    </a>",
"    ]. Although median time to sputum culture conversion was better in the vitamin D group (36 versus 43.5 days with placebo), the results were not statistically significant (HR 1.39, 95% CI 0.90-2.16). Thus, there is currently insufficient data to define a role for vitamin D in the prevention or treatment of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D supplementation also did not reduce the rate of exacerbations in the majority of patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/49\">",
"     49",
"    </a>",
"    ]. Compared with placebo, high dose vitamin D supplementation (100,000 int. units of vitamin D3 every four weeks for 12 months) in severe COPD patients showed no benefit on time to first exacerbation (usually a new infection) or exacerbation rates, except in patients with a baseline 25OHD level below 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\", section on 'Prevention'",
"    </a>",
"    .) In addition, supplementation with vitamin D in children with poor vitamin D status did not improve the risk of pneumonia in infants living in Kabul [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a hypothesis that common virologic infections have a marked seasonal variation because of the seasonal variation of the vitamin D status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, a causal relationship between vitamin D and viral infections has not been established. As an example, in a randomized trial of vitamin D (2000 units D3 daily) or matching placebo in 162 adults for 12 weeks during the winter season, there was no difference in the incidence of upper respiratory infections between the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/53\">",
"     53",
"    </a>",
"    ]. Similar findings were noted among 164 Finnish military recruits who were randomly assigned to vitamin D (400 units D3 daily) versus placebo for six months during the winter season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/54\">",
"     54",
"    </a>",
"    ] and among 322 healthy adults with a mean baseline 25-hydroxyvitamin D level of 29",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (72",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    who were randomly assigned to high dose vitamin D (200,000 units monthly for two months followed by 100,000 units monthly) or placebo for 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/55\">",
"     55",
"    </a>",
"    ]. There were no differences in the number of upper respiratory tract infection events, days absent from duty due to acute respiratory tract infection, in self reported symptoms of acute respiratory infection (cough, runny nose, sore throat, fever), or in hospitalization due to acute respiratory infection. In contrast, compared with ingestion of unfortified milk, daily ingestion of milk fortified with 300 int. units of vitamin D3 did decrease the risk of acute respiratory infections in Mongolian children with baseline median serum 25OHD level of 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (17.5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several ongoing randomized trials to clarify the possible beneficial effects of vitamin D supplementation on infectious diseases (see NIH and European clinical trial registers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the VDR-vitamin D endocrine system can modulate most aspects of the innate and acquired immune system (and even mast cells) when challenged by extreme deficiency or exposure to high 1,25-(OH)2D (or its analogs). However, vitamin D supplementation does not appear to reduce the incidence of upper respiratory infections in healthy adults with normal or near-normal serum 25-hydroxyvitamin D levels. The causal link between poor vitamin D status and autoimmune diseases or infections in humans remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651676\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR DISEASES AND HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is geographic and racial variation in blood pressure, with risk of hypertension increasing from south to north in the Northern hemisphere. One proposed explanation for the association with latitude is that exposure to sunlight may be protective, either because of an effect of ultraviolet radiation or of vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/59\">",
"     59",
"    </a>",
"    ]. In animal studies, 1,25-dihydroxyvitamin D has been shown to regulate the renin-angiotensin system. Vitamin D receptor null mice or mice with inborn deficiency of the 1&alpha;-hydroxylase gene develop high renin hypertension and cardiac hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. Moreover, vascular endothelial and smooth muscle cells respond to exposure to 1,25-dihydroxyvitamin D with a &ldquo;favorable cardioprotective&rdquo; gene response. This corresponds well with reduced thrombogenesis and increased fibrinolysis as observed in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies are consistent with these preclinical data. In normotensive and hypertensive individuals, there is an inverse association between 25OHD concentration and blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. The link between vitamin D status and hypertension is complicated by a strong negative association between BMI, a well known risk factor for hypertension, and 25OHD. Prospective randomized intervention trials are therefore needed to prove causality and, if present, to define the optimal dose for each target population. A meta-analysis of eight randomized trials examining the effects of vitamin D supplementation on blood pressure in hypertensive",
"    <span class=\"nowrap\">",
"     (&ge;140/90",
"    </span>",
"    mm Hg) men and women showed a small but significant reduction in diastolic blood pressure (-3.1 mm Hg, 95% CI -5.5 to -0.6) and a nonsignificant reduction in systolic blood pressure (-3.6 mmHg, 95% CI -8.0 to 0.7) in the vitamin D group compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/65\">",
"     65",
"    </a>",
"    ]. In a subsequent meta-analysis of 10 trials (including four trials included in the previous meta-analysis), there was a nonsignificant reduction in systolic blood pressure (weighted mean difference -1.9 mm Hg) with vitamin D supplementation, but no effect on diastolic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/66\">",
"     66",
"    </a>",
"    ]. Thus, additional trials are required to confirm or refute a beneficial effect on blood pressure.",
"   </p>",
"   <p>",
"    The link between vitamin D and cardiovascular disease involves a much broader spectrum of cardiovascular risks beyond its association with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/67\">",
"     67",
"    </a>",
"    ]. In a meta-analysis of 19 prospective studies (65,994 patients), there was an inverse relationship between serum 25OHD levels (ranging from 8 to 24",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [20 to 60",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    and risk of cardiovascular disease (RR of 1.03, 95% CI 1.00-1.60, per 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [25",
"    <span class=\"nowrap\">",
"     nmol/L]",
"    </span>",
"    decrement in serum 25OHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/68\">",
"     68",
"    </a>",
"    ]. Examples of individual studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Framingham Offspring Study, participants who had a 25OHD &lt;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (37.5",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      were more likely to have their first cardiovascular event during 5.4 years (mean) of observation than those with values &ge;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (hazard ratio [HR] 1.62, 95% CI 1.11-2.36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the National Health and Nutrition Examination Study (NHANES) 2001 to 2004, the prevalence of coronary heart disease (angina, myocardial infarction) was more common in adults with 25OHD levels &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      compared with &ge;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (odds ratio adjusted for age, race, and gender 1.49, 95% CI 1.17-1.91) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. Adjusting for other risk factors (body mass index, chronic kidney disease, hypertension, diabetes mellitus, smoking, use of vitamin D supplements) attenuated the association (OR 1.24, 95% CI 0.95-1.62). The prevalence of heart failure and peripheral arterial diseases was also higher among those with 25OHD values &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (ORs 2.10 and 1.82, respectively) with similar attenuation after adjustment for other risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a review of four interventional randomized trials and a meta-analysis of six trials, however, there was no effect of supplementation on cardiovascular outcomes, including myocardial infarction and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/66,72\">",
"     66,72",
"    </a>",
"    ]. The meta-analysis also did not show a significant effect of vitamin D supplementation on cardiovascular risk factors (lipids, glucose, blood pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/72\">",
"     72",
"    </a>",
"    ]. In one of the larger trials included in the meta-analysis, there was no beneficial effect on cardiovascular or metabolic risks after increasing baseline 25OHD levels from 23 to well above 40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (58 to 100",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent randomized trial of an active vitamin D preparation (oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"     paricalcitol",
"    </a>",
"    ) versus placebo in 227 patients with chronic kidney disease (estimated glomerular filtration rate 15 to 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2), there was no difference in left ventricular mass index or improvement in measures of diastolic dysfunction between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, the causal nature of the association between vitamin D and cardiovascular disease remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651683\">",
"    <span class=\"h1\">",
"     DIABETES AND METABOLIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of reasons to link type 1 and type 2 diabetes with vitamin D status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/75\">",
"     75",
"    </a>",
"    ]. For type 1 diabetes, the link is largely mediated by the effects of vitamin D on the immune system. (See",
"    <a class=\"local\" href=\"#H14670995\">",
"     'Acquired'",
"    </a>",
"    above.) For type 2 diabetes, the potential mechanisms include improving both &beta; cell activity as well as insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In several studies, obesity was associated with low 25OHD concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, in several cross-sectional studies, type 2 diabetes and conditions known to be part of the metabolic syndrome were associated with a poor vitamin D status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. However, in a systematic review of three longitudinal cohort studies, the association was not consistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/66\">",
"     66",
"    </a>",
"    ]. In one cohort, there was an association between higher vitamin D concentrations and lower risk for developing diabetes in men but not women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/82\">",
"     82",
"    </a>",
"    ]. In contrast, in the Women&rsquo;s Health Initiative Study, there was an association between higher total vitamin D intake and lower risk for type 2 diabetes (adjusted OR 0.73, 95% CI 0.54-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/83\">",
"     83",
"    </a>",
"    ]. In a subsequent analysis using data from the 1972 Framingham Offspring Study, individuals in the highest tertile of a predicted vitamin D score at baseline had a lower incidence of type 2 diabetes than those in the lowest tertile (HR 0.60, 95% CI 0.37-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intervention studies are mostly negative. In a meta-analysis of eight trials evaluating the effect of vitamin D supplementation on glycemia, there was no effect of supplementation on glycemia or incident diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/66\">",
"     66",
"    </a>",
"    ]. However, a subsequent trial in severely vitamin D deficient Asians living in New Zealand revealed a modest improvement of their insulin sensitivity after six months of vitamin D supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, vitamin D status is lower in individuals with type 2 diabetes, but the causality of this relationship is unknown. Poor vitamin D status is also frequently linked with nearly all elements of the metabolic syndrome, but the existing intervention studies are either negative or showed only limited beneficial effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/73,86,87\">",
"     73,86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651690\">",
"    <span class=\"h1\">",
"     NEUROPSYCHIATRIC FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitamin D receptor and the 1&alpha;-hydroxylase enzyme that converts vitamin D to its active form are expressed in the human brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/88\">",
"     88",
"    </a>",
"    ]. Through its effects on neuronal proliferation, differentiation, migration, and apoptosis, vitamin D may play an important role in brain development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. In addition, it has been proposed that prenatal vitamin D deficiency may increase the risk of neuropsychiatric disorders, such as schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/91\">",
"     91",
"    </a>",
"    ]. There are inconsistent small effects of vitamin D deficiency on postnatal brain function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/92\">",
"     92",
"    </a>",
"    ]. Low levels of 25OHD are frequently found in patients with depression or Alzheimer&rsquo;s disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], and a meta-analysis of observational studies showed lower Mini-Mental State Examination scores in patients with lower serum vitamin D concentrations (25OHD &lt;20 versus &ge;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;50 versus &ge;50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link&amp;anchor=H418326#H418326\">",
"     \"Risk factors for dementia\", section on 'Vitamin D deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few trials evaluating the effects of vitamin D supplementation on neuropsychiatric symptoms. In one trial, 243 patients with depression and low serum 25-hydroxyvitamin D levels (mean 19",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [47",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    were randomly assigned to vitamin D supplementation (40,000 int. units weekly) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/95\">",
"     95",
"    </a>",
"    ]. After six months, there were no differences in depressive symptom scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/95\">",
"     95",
"    </a>",
"    ]. Thus, the causal nature of the association between vitamin D and neuropsychiatric function remains uncertain. Vitamin D deficiency in this population may be a consequence of their limited mobility and sun exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651697\">",
"    <span class=\"h1\">",
"     GENES AND VITAMIN D STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin studies suggest a high degree of heritability of serum 25OHD levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/96\">",
"     96",
"    </a>",
"    ]. A very large international consortium identified four gene polymorphisms that were strongly associated with serum 25OHD levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/97\">",
"     97",
"    </a>",
"    ]. In addition, a meta-analysis of cohort studies identified common polymorphisms in the vitamin D receptor gene that significantly modified the association of serum 25OHD and major health outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/98\">",
"     98",
"    </a>",
"    ]. Thus,",
"    <strong>",
"    </strong>",
"    part of the large inter-individual variation in 25OHD levels in normal subjects living in very comparable situations and the risk of adverse health outcomes associated with low serum 25OHD levels may be purely genetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651704\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/99-106\">",
"     99-106",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/107,108\">",
"     107,108",
"    </a>",
"    ], epidemiologic studies suggest that low 25OHD levels (especially &lt;10 to 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [25 to 50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    are associated with higher mortality. In some of these studies, the relationship between serum 25OHD and mortality was defined by a U or reverse J-shaped curve, indicating higher mortality at very low (&lt;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and high (&gt;30 to 50",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    75 to 125",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    serum 25OHD concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/32,100,103\">",
"     32,100,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data regarding cause specific mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/26,109\">",
"     26,109",
"    </a>",
"    ]. In The Third National Health and Nutrition Examination Survey, there was no association between serum 25OHD levels and cardiovascular death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/100\">",
"     100",
"    </a>",
"    ] or overall cancer mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/110\">",
"     110",
"    </a>",
"    ]. In men, cancer mortality was significantly higher at the highest quintiles of 25OHD (RRs 1.66 and 1.85 for those with 25OHD levels of 32 to 40 and &ge;40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [80 to 100 and &ge;100",
"    <span class=\"nowrap\">",
"     nmol/L],",
"    </span>",
"    respectively). When the risk for particular cancer sites was evaluated, there was a significant positive association between 25OHD levels and risk of mortality from lung cancer and an inverse association between 25OHD levels and colorectal cancer, which did not reach statistical significance. There was no relationship between 25OHD levels and cancer mortality in women. An association between higher baseline serum 25OHD concentrations and higher total cancer mortality among men, but not women, has also been reported in other prospective cohort studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/26,107,111\">",
"     26,107,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials of vitamin D supplementation with mortality as a primary endpoint are lacking. In a meta-analysis of 18 randomized trials primarily designed to evaluate the effect of vitamin D supplementation on fracture prevention, there was a significant reduction in all-cause mortality (RR 0.93, 95% CI 0.87-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/112\">",
"     112",
"    </a>",
"    ]. However, in subsequent meta-analyses which included a larger number of trials (50 and 51 trials), the reduction in mortality with vitamin D supplementation did not reach statistical significance (RR 0.96, 95% CI 0.93-1.00) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/72,113\">",
"     72,113",
"    </a>",
"    ]. Since mortality was not reported in all trials, there is the possibility of reporting bias where trials showing a mortality effect would be more likely to include results on mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15412563\">",
"    <span class=\"h1\">",
"     OPTIMAL VITAMIN D FOR EXTRASKELETAL HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a large number of epidemiologic data indicating that the risks of cancer, infectious, autoimmune, and cardiovascular diseases are higher when 25OHD levels are &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and that risks decrease with higher 25OHD concentrations. However, there are no convincing randomized trial data that vitamin D supplements can decrease cancer risk or prognosis, decrease the risk or severity of infections or autoimmune diseases, or decrease cardiovascular risks or metabolic diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/87,114\">",
"     87,114",
"    </a>",
"    ]. In addition, there are no prospective studies to define optimal 25OHD levels for extra-skeletal health. Thus, we do not suggest vitamin D supplementation above and beyond what is required for osteoporosis or fall prevention. (See",
"    <a class=\"local\" href=\"#H651654\">",
"     'Falls'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .) This recommendation is consistent with the recommendations of The Standing Committee of European Doctors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31193/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651711\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to its role in calcium and bone homeostasis, vitamin D potentially regulates many other cellular functions. (See",
"      <a class=\"local\" href=\"#H651633\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin D supplementation (700 to 1000",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      reduces the risk of falls in elderly populations. However, a causal association between poor vitamin D status and nearly all major diseases (cancer, infections, autoimmune diseases, cardiovascular and metabolic diseases) has not been established. (See",
"      <a class=\"local\" href=\"#H651654\">",
"       'Falls'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15412563\">",
"       'Optimal vitamin d for extraskeletal health'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not administering vitamin D supplements above and beyond what is required for osteoporosis or fall prevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H651654\">",
"       'Falls'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of vitamin D deficiency is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"       \"Treatment of vitamin D deficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/1\">",
"      Prentice A. Vitamin D deficiency: a global perspective. Nutr Rev 2008; 66:S153.",
"     </a>",
"    </li>",
"    <li>",
"     Bouillon R. Vitamin D: from photosynthesis, metabolism and action to clinical applications. In: Endocrinology, Jameson JL, De Groot LJ (Eds), Saunders Elsevier, Philadelphia 2010. Vol 1, p.1089.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/3\">",
"      Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/4\">",
"      Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/5\">",
"      Girgis CM, Clifton-Bligh RJ, Hamrick MW, et al. The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev 2013; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/6\">",
"      Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/7\">",
"      Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000; 66:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/8\">",
"      Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged &gt; or =60 y. Am J Clin Nutr 2004; 80:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/9\">",
"      Visser M, Deeg DJ, Lips P, Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88:5766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/10\">",
"      Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 2007; 92:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/11\">",
"      Annweiler C, Schott AM, Berrut G, et al. Vitamin D-related changes in physical performance: a systematic review. J Nutr Health Aging 2009; 13:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/12\">",
"      Zhu K, Austin N, Devine A, et al. A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency. J Am Geriatr Soc 2010; 58:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/13\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/14\">",
"      Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM 2007; 100:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/15\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339:b3692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/16\">",
"      Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009; :CD007146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/17\">",
"      Cameron ID, Murray GR, Gillespie LD, et al. Interventions for preventing falls in older people in nursing care facilities and hospitals. Cochrane Database Syst Rev 2010; :CD005465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/18\">",
"      Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:2997.",
"     </a>",
"    </li>",
"    <li>",
"     Apperly, FL. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941; 1:1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/20\">",
"      Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/21\">",
"      Bouillon R, Eelen G, Verlinden L, et al. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006; 102:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/22\">",
"      Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004; 80:1721S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/23\">",
"      Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005; 16:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/24\">",
"      Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004; 13:1502.",
"     </a>",
"    </li>",
"    <li>",
"     IARC. Vitamin D and Cancer. IARC Working Group Reports Vol.5, International Agency for research on Cancer, Lyon. November 2008. file://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report_VitD.pdf .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/26\">",
"      Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/27\">",
"      Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 2010; 340:b5500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/28\">",
"      Weinstein SJ, Yu K, Horst RL, et al. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol 2011; 173:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/29\">",
"      Stolzenberg-Solomon RZ, Vieth R, Azad A, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006; 66:10213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/30\">",
"      Helzlsouer KJ, VDPP Steering Committee. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/31\">",
"      Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:81.",
"     </a>",
"    </li>",
"    <li>",
"     file://books.nap.edu/openbook.php?record_id=13050&amp;page=366 (Accessed on January 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/33\">",
"      Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/34\">",
"      Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/35\">",
"      Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/36\">",
"      Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008; 100:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/37\">",
"      Ponsonby AL, McMichael A, van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 2002; 181-182:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/38\">",
"      Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005; 48:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/39\">",
"      Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/40\">",
"      Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/41\">",
"      Lange NE, Litonjua A, Hawrylowicz CM, Weiss S. Vitamin D, the immune system and asthma. Expert Rev Clin Immunol 2009; 5:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/42\">",
"      Gale CR, Robinson SM, Harvey NC, et al. Maternal vitamin D status during pregnancy and child outcomes. Eur J Clin Nutr 2008; 62:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/43\">",
"      Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/44\">",
"      Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008; 37:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/45\">",
"      Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 2006; 38:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/46\">",
"      Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009; 179:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/47\">",
"      Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/48\">",
"      Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev 2011; :CD006086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/49\">",
"      Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012; 156:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/50\">",
"      Manaseki-Holland S, Maroof Z, Bruce J, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet 2012; 379:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/51\">",
"      Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/52\">",
"      Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/53\">",
"      Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect 2009; 137:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/54\">",
"      Laaksi I, Ruohola JP, Mattila V, et al. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. J Infect Dis 2010; 202:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/55\">",
"      Murdoch DR, Slow S, Chambers ST, et al. Effect of Vitamin D3 Supplementation on Upper Respiratory Tract Infections in Healthy Adults: The VIDARIS Randomized Controlled Trial. JAMA 2012; 308:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/56\">",
"      Camargo CA Jr, Ganmaa D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 2012; 130:e561.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/results?term=Vitamin+D+and+infection (Accessed on August 05, 2010).",
"    </li>",
"    <li>",
"     https://eudract.emea.europa.eu/ (Accessed on August 05, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/59\">",
"      Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/60\">",
"      Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/61\">",
"      Bouillon R. Vitamin D as potential baseline therapy for blood pressure control. Am J Hypertens 2009; 22:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/62\">",
"      Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/63\">",
"      Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/64\">",
"      Schmitz KJ, Skinner HG, Bautista LE, et al. Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens 2009; 22:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/65\">",
"      Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens 2009; 27:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/66\">",
"      Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/67\">",
"      McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med 2011; 155:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/68\">",
"      Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012; 5:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/69\">",
"      Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/70\">",
"      Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/71\">",
"      Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009; 205:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/72\">",
"      Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/73\">",
"      Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010; 267:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/74\">",
"      Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/75\">",
"      Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am 2010; 39:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/76\">",
"      Ozfirat Z, Chowdhury TA. Vitamin D deficiency and type 2 diabetes. Postgrad Med J 2010; 86:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/77\">",
"      Zhao G, Ford ES, Li C. Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among U.S. adults without physician-diagnosed diabetes: NHANES, 2003-2006. Diabetes Care 2010; 33:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/78\">",
"      Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010; 33:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/79\">",
"      Kositsawat J, Freeman VL, Gerber BS, Geraci S. Association of A1C levels with vitamin D status in U.S. adults: data from the National Health and Nutrition Examination Survey. Diabetes Care 2010; 33:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/80\">",
"      Cheng S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 2010; 59:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/81\">",
"      Reis JP, von M&uuml;hlen D, Miller ER 3rd, et al. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009; 124:e371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/82\">",
"      Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008; 19:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/83\">",
"      Liu S, Song Y, Ford ES, et al. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005; 28:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/84\">",
"      Liu E, Meigs JB, Pittas AG, et al. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study. Am J Clin Nutr 2010; 91:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/85\">",
"      von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 2010; 103:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/86\">",
"      Wang H, Xia N, Yang Y, Peng DQ. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis 2012; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/87\">",
"      Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012; 33:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/88\">",
"      Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/89\">",
"      Eyles DW, Feron F, Cui X, et al. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009; 34 Suppl 1:S247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/90\">",
"      Holm&oslash;y T, Moen SM. Assessing vitamin D in the central nervous system. Acta Neurol Scand Suppl 2010; :88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/91\">",
"      McGrath J. Does 'imprinting' with low prenatal vitamin D contribute to the risk of various adult disorders? Med Hypotheses 2001; 56:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/92\">",
"      Tuohimaa P, Keisala T, Minasyan A, et al. Vitamin D, nervous system and aging. Psychoneuroendocrinology 2009; 34 Suppl 1:S278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/93\">",
"      Lee DM, Tajar A, O'Neill TW, et al. Lower vitamin D levels are associated with depression among community-dwelling European men. J Psychopharmacol 2011; 25:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/94\">",
"      Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology 2012; 79:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/95\">",
"      Kj&aelig;rgaard M, Waterloo K, Wang CE, et al. Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial. Br J Psychiatry 2012; 201:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/96\">",
"      Hunter D, De Lange M, Snieder H, et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 2001; 16:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/97\">",
"      Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/98\">",
"      Levin GP, Robinson-Cohen C, de Boer IH, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012; 308:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/99\">",
"      Hagenau T, Vest R, Gissel TN, et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int 2009; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/100\">",
"      Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/101\">",
"      Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009; 57:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/102\">",
"      Virtanen JK, Nurmi T, Voutilainen S, et al. Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr 2011; 50:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/103\">",
"      Jia X, Aucott LS, McNeill G. Nutritional status and subsequent all-cause mortality in men and women aged 75 years or over living in the community. Br J Nutr 2007; 98:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/104\">",
"      Zhao G, Ford ES, Li C, Croft JB. Serum 25-hydroxyvitamin D levels and all-cause and cardiovascular disease mortality among US adults with hypertension: the NHANES linked mortality study. J Hypertens 2012; 30:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/105\">",
"      Zittermann A, Iodice S, Pilz S, et al. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012; 95:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/106\">",
"      Sch&ouml;ttker B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/107\">",
"      Cawthon PM, Parimi N, Barrett-Connor E, et al. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab 2010; 95:4625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/108\">",
"      Lin SW, Chen W, Fan JH, et al. Prospective study of serum 25-hydroxyvitamin D concentration and mortality in a Chinese population. Am J Epidemiol 2012; 176:1043.",
"     </a>",
"    </li>",
"    <li>",
"     Chung, M, Balk, EM, Brendel, M, Ip, S, Lau, J, Lee, J, Lichtenstein, AH, Patel, K, Raman, G, Tatsioni, A, Terasawa, T, and Trikalinos, T. The relationship of vitamin D and calcium intakes to nutrient status indicators and health outcomes. Evidence Report No. XXX (prepared by the Tufts Evidence-based Practice Center under Contract No. HHSA-290-2007-10055-1). AHRQ publication No. 0X-E0XX. Rockville, MD: Agency for Healthcare Research and Quality. June 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/110\">",
"      Freedman DM, Looker AC, Abnet CC, et al. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 2010; 70:8587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/111\">",
"      Micha&euml;lsson K, Baron JA, Snellman G, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 2010; 92:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/112\">",
"      Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/113\">",
"      Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2011; :CD007470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31193/abstract/114\">",
"      Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science 2012; 337:1476.",
"     </a>",
"    </li>",
"    <li>",
"     The Standing Committee of European Doctors. Vitamin D nutritional policy in Europe, 2009. file://cpme.dyndns.org:591/adopted/2009/CPME_AD_Brd_241009_179_final_EN.pdf (Accessed on September 21, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13915 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.124.72.62-24570E3F92-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31193=[""].join("\n");
var outline_f30_29_31193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H651711\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651633\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651640\">",
"      MUSCLE FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651647\">",
"      Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651654\">",
"      Falls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651662\">",
"      CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651669\">",
"      IMMUNE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14670995\">",
"      Acquired",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14671002\">",
"      Innate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651676\">",
"      CARDIOVASCULAR DISEASES AND HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651683\">",
"      DIABETES AND METABOLIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651690\">",
"      NEUROPSYCHIATRIC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651697\">",
"      GENES AND VITAMIN D STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651704\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15412563\">",
"      OPTIMAL VITAMIN D FOR EXTRASKELETAL HEALTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651711\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_29_31194="Pharmacologic agents for pediatric procedural sedation outside of the operating room";
var content_f30_29_31194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Deborah C Hsu, MD, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Joseph P Cravero, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/29/31194/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/29/31194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7977200\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of short-acting sedative-hypnotic and analgesic medications are available for pediatric procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Many of these agents have multiple routes of administration. The choice of drug is based upon the type of procedure and the patient's underlying medical condition. Procedures that are not painful but require the child to remain still can usually be performed with sedation alone. Children undergoing painful procedures require analgesia as well as sedation.",
"   </p>",
"   <p>",
"    This topic will discuss the properties of agents commonly used for procedural sedation in children outside of the operating room.",
"   </p>",
"   <p>",
"    Assessment, preparation, and proper performance of procedural sedation outside of the operating room, including selection of medications for pediatric procedural sedation, and sedation in adults are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7977207\">",
"    <span class=\"h1\">",
"     SEDATIVE-HYPNOTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs provide sedation, motion control, anxiolysis, and, to varying degrees, amnesia but, with the exception of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    , do",
"    <strong>",
"     not",
"    </strong>",
"    provide analgesia. The properties of commonly used agents for pediatric procedural sedation are provided and summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When used for procedural sedation in children, these agents should",
"    <strong>",
"     only",
"    </strong>",
"    be administered by properly trained and experienced clinicians. All children require careful pre-sedation evaluation. The clinician should develop a sedation plan that provides appropriate targeted level of sedation (mild, moderate, or deep) as determined by patient characteristics, anticipated degree of procedural pain, and procedural requirements. Appropriate monitoring, personnel and equipment must also be in place during the sedation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560692#H1560692\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Pre-sedation evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link&amp;anchor=H1683215#H1683215\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Performing procedural sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selection of medications for pediatric procedural sedation is determined by patient factors, anticipated degree of pain, and type of procedure and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253043#H2253043\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Choice of sedative agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3220172\">",
"    <span class=\"h2\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     Propofol",
"    </a>",
"    is a nonopioid, nonbarbiturate sedative hypnotic that has historically been extensively used by anesthesiologists and intensivists as an induction agent for general anesthesia, and as a sedative in intensive care units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Over the past 2 decades propofol has also been used extensively for procedural sedation in sedation units, emergency departments and radiology suites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The decision to use propofol and whether it is used with other agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) should depend on the duration and the nature of the procedure being performed.",
"   </p>",
"   <p>",
"    Practitioners who choose to use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    alone or in combination with other medications for brief procedural sedation outside of the operating room must vigilantly adhere to protocols that include careful monitoring with capnography as well as pulse oximetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/10\">",
"     10",
"    </a>",
"    ]. Use must be consistent with hospital guidelines and protocols, local regulations, and the practitioner's privilege delineation. In some regions, propofol is",
"    <strong>",
"     only",
"    </strong>",
"    approved for use by anesthesiologists or others with specialized pediatric procedural sedation training. Otherwise, bolus propofol use for sedation in children may be considered unlicensed. Clinicians should check local recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash; When used for prolonged sedation (eg, during magnetic resonance imaging),",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      is often given as a continuous infusion. Although the manufacturer&rsquo;s recommended starting dose is 25",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute, a typical effective starting dose of 100 to 150",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute is frequently used by experienced practitioners [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,11\">",
"       2,11",
"      </a>",
"      ]. The infusion dose is then gradually increased as needed to achieve adequate sedation up to a maximum dose of 200",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute.",
"      <br/>",
"      <br/>",
"      For brief procedures, propofol may also be administered as a continuous infusion or as an initial intravenous (IV) bolus dose of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in infants and children between six months and two years of age) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/11\">",
"       11",
"      </a>",
"      ]. When propofol is combined with other agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      ), the initial bolus dose of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is suggested. Repeated doses of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of IV propofol may be given every three to five minutes up to a maximum total dose of 3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      as needed to achieve the desired effect. Relative to a continuous infusion, bolus dosing of propofol increases the risk of exceeding the desired level of sedation and is associated with a higher likelihood of respiratory depression, bradycardia, and hypotension, especially when combined with opioid medications.",
"      <br/>",
"      <br/>",
"      Propofol doses should be reduced by approximately 50 percent or alternative sedation regimens considered, for children with reduced cardiac output, hypovolemia, or debilitation and in these patients, consultation with an anesthesiologist or pediatric critical care specialist is advised.",
"      <br/>",
"      <br/>",
"      Propofol causes pain during IV administration that can be reduced by IV pretreatment with 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of systemic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      injected into the vein with a tourniquet applied for one minute or by administration of ketamine or an opioid prior to propofol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2\">",
"       2",
"      </a>",
"      ]. Pain is also lessened by injecting into an antecubital rather than a hand vein.",
"     </li>",
"     <li>",
"      <strong>",
"       Benefits",
"      </strong>",
"      &ndash; Compared to other commonly used agents,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      has the fastest onset of action and one of the shortest recovery times (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ). Propofol reduces intracranial pressure, making it a good choice in hemodynamically stable patients with head trauma. Studies indicate high efficacy for successful completion of diagnostic imaging and, when combined with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      , a variety of painful procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash; Adverse effects requiring routine intervention by appropriately trained providers occur in approximately 2 to 5 percent of children undergoing",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      sedation and include respiratory depression, apnea, and hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/6,15-17\">",
"       6,15-17",
"      </a>",
"      ]. Respiratory arrest requiring endotracheal intubation, pulmonary aspiration, and cardiorespiratory arrest have all been described but occur rarely when sedation is performed by well-trained physicians as part of an organized sedation service [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/7,14\">",
"       7,14",
"      </a>",
"      ]. Because of the rapid onset of action and high potency of the drug, it is more difficult to titrate and can rapidly achieve a greater depth of sedation than intended, especially when given in bolus doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash; Formulations of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      contain egg lecithin, egg yolk phospholipids, and soybean oil. Consequently, some suggest that children with allergies to egg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soybeans should not receive propofol, whenever possible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/19\">",
"       19",
"      </a>",
"      ]. In one case series of 28 children with documented egg allergy who received 43 doses of propofol, allergic reaction, consisting of urticaria and erythema, occurred in one instance (2 percent of administrations) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/20\">",
"       20",
"      </a>",
"      ]. The frequency of allergic reactions in children with soy allergy who receive propofol is not known.",
"      <br/>",
"      <br/>",
"      Prolonged propofol infusions in critically ill pediatric patients have been associated with the propofol infusion syndrome, an acute refractory bradycardia that progresses to asystole in combination with metabolic acidosis, rhabdomyolysis, hyperlipidemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fatty liver. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25082?source=see_link\">",
"       \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3220179\">",
"    <span class=\"h2\">",
"     Dexmedetomidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"     Dexmedetomidine",
"    </a>",
"    is a selective alpha-2 adrenergic receptor agonist that offers potent sedative effects along with some analgesia. Unlike most sedatives, it causes minimal respiratory depression. In 2008, the US Food and Drug Administration approved dexmedetomidine for sedation of patients prior to or during surgical or other procedures. As a relatively new agent for pediatric procedural sedation, the experience with the drug is still limited, and its scope of use is evolving. In healthy children, dexmedetomidine has been found to be generally safe and effective for nonpainful procedures (eg, neuroimaging) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/11\">",
"     11",
"    </a>",
"    ]. In some sedation services, dexmedetomidine is the preferred agent to sedate for diagnostic imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash; Based upon its pharmacokinetic profile in adults, the manufacturer recommends an initial intravenous (IV) bolus of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      over 10 minutes followed by a constant infusion of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour. However, the doses necessary to accomplish effective pediatric sedation with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      alone tend to be",
"      <strong>",
"       higher",
"      </strong>",
"      than the manufacturer&rsquo;s recommendation with the most efficacious response seen when administering a 2 to 3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      IV bolus dose of dexmedetomidine followed by a continuous infusion of 1 to 2",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour.",
"      <br/>",
"      <br/>",
"      Alternatively, administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      with manufacturer-recommended dosing of dexmedetomidine as above can improve efficacy (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/12,22-24\">",
"       12,22-24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Dexmedetomidine may also be administered to children via the intranasal or buccal routes although no studies exist regarding the use of these routes for pediatric procedural sedation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intranasal (1.5",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      has been shown in several studies to produce sedation that is similar to oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      at 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and is associated with lower post-procedural pain scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Buccal administration of 3 to 4",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      results in moderate sedation without reported respiratory complications based upon perioperative studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Benefits",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      provides effective pediatric sedation with a very low potential for respiratory depression. Although onset of action is slower than other intravenous agents with a somewhat longer recovery time, recovery agitation is minimal (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ). Dexmedetomidine has also achieved high efficacy for successful completion of nonpainful diagnostic studies in children with autism and other behavioral disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/11,29\">",
"       11,29",
"      </a>",
"      ]. In addition, dexmedetomidine is particularly useful when weaning mechanically ventilated children from ventilators since it is not associated with respiratory depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Based upon human volunteer and animal studies, atipamezole, a selective alpha-2 adrenergic receptor antagonist, is an effective reversal agent for dexmedetomidine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/32\">",
"       32",
"      </a>",
"      ]. Atipamezole is routinely administered by veterinarians to reverse sedation in animals. However, it is rarely used to reverse dexmedetomidine sedation in humans.",
"     </li>",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash; Hypertension has been described in up to 5 percent of patients receiving",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      . This adverse effect is associated with younger patient age and multiple boluses of the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/23\">",
"       23",
"      </a>",
"      ]. Moderate decreases in heart rate and blood pressure outside the normal range for age occur in up to 30 percent of children who receive dexmedetomidine. Hypertension is dose-related and typically resolves without specific treatment or with discontinuation of the infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Hypotension during the initial bolus dose of dexmedetomidine is usually reversed with a fluid bolus. In contrast, profound bradycardia has been described in patients who have conduction system pathology or who are receiving AV nodal slowing medications such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      should be avoided in children who are receiving medicines with rate slowing action on the AV node (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/2/9256?source=see_link\">",
"       nifedipine",
"      </a>",
"      ), cardiac conduction system pathology, and those in whom increased pulmonary artery pressure or decreased cardiac output are unlikely to be well tolerated (eg, right-sided heart failure, septic shock) unless it is provided by clinicians with training and expertise in cardiac anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      to treat bradycardia caused by dexmedetomidine has been associated with severe hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/35\">",
"       35",
"      </a>",
"      ]. Thus, the use of glycopyrrolate and other anticholinergic agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      ) should be avoided in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2606114\">",
"    <span class=\"h2\">",
"     Etomidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"     Etomidate",
"    </a>",
"    is an imidazole, nonbarbiturate hypnotic agent with an ultrashort onset of action (5 to 30 seconds). In healthy patients (American Society of Anesthesia class I or II) (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"mobipreview.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ), duration of effect is also short (5 to 15 minutes) and depends upon the initial dose. Rapid recovery results from drug redistribution. The duration of effect is prolonged in patients with hepatic or renal dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      is given as an intravenous (IV) bolus dose of 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2\">",
"       2",
"      </a>",
"      ]. Repeated doses of 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      may be given every five minutes up to a maximum total dose of 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to achieve the desired effect.",
"      <br/>",
"      <br/>",
"      Etomidate causes pain during IV administration that can be reduced by IV pretreatment with 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of systemic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      that is injected into the vein one minute prior to etomidate with a tourniquet applied. Pain is also lessened by injecting into an antecubital rather than a hand vein.",
"     </li>",
"     <li>",
"      <strong>",
"       Benefits",
"      </strong>",
"      &ndash; Rapid onset of action and recovery with few residual effects make",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      useful for sedation during brief nonpainful procedures, especially for children who require ongoing clinical assessment of consciousness (eg, patients with head injury) (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ). Etomidate also reduces intracranial pressure and maintains hemodynamic stability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/11\">",
"       11",
"      </a>",
"      ]. Thus, it is a good choice for sedating patients in whom cardiovascular status is uncertain or compromised (eg, multiple system trauma patients). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253064#H2253064\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Intravenous medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash; The frequency of adverse events when",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      is given as a single agent for pediatric procedural sedation is approximately 1 percent. The most commonly reported adverse events include respiratory depression, vomiting, and nonepileptiform myoclonus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,11,36\">",
"       2,11,36",
"      </a>",
"      ]. Adverse events may be more frequent when etomidate is combined with an opioid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The frequency of nonepileptiform myoclonus in children receiving etomidate as a single agent for nonpainful procedures appears to be lower than in adults (&lt;1 percent versus up to 80 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/36\">",
"       36",
"      </a>",
"      ]. In adults, small trials suggest that premedication with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      , or etomidate 0.03 to 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      significantly reduces the frequency of myoclonus. However, given the lower frequency of myoclonus in children, the routine administration of any of these drugs appears unwarranted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H16#H16\">",
"       \"Procedural sedation in adults\", section on 'Etomidate'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If myoclonus occurs during pediatric procedural sedation, IV midazolam is suggested [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      inhibits 11-beta hydroxylase, an enzyme important for adrenal steroid production and is contraindicated in patients with known adrenal insufficiency. Adrenal suppression from single doses of etomidate has not been associated with any negative outcomes in healthy children undergoing procedural sedation. Acute adrenal insufficiency and increased mortality have been associated with single doses of etomidate in children with severe sepsis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=see_link&amp;anchor=H19450192#H19450192\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Airway and breathing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7977214\">",
"    <span class=\"h2\">",
"     Midazolam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    is a short-acting benzodiazepine with a rapid onset of action when given intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2\">",
"     2",
"    </a>",
"    ]. It has good anxiolytic, amnestic, and muscle relaxant properties and has been frequently used to provide mild sedation in children or combined with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    to achieve moderate sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3,11\">",
"     2,3,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      is water soluble and can be given by parenteral (intravenous or intramuscular), rectal (PR), intranasal (IN), sublingual (SL), or oral (PO) routes. Doses, onset of action, and duration of effect will vary depending upon patient age and the route of administration (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3,11\">",
"       2,3,11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When compared to PR, SL, or PO administration, IN midazolam has the most rapid onset of action and shortest recovery time (",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/3\">",
"       3",
"      </a>",
"      ]. However, intranasal midazolam can be very irritating for some children. Pretreatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      spray (10 mg per puff) one minute prior to IN administration decreases nasal mucosal irritation. An atomizer can deliver midazolam intranasally with better comfort and with reduction of sneezing and cough when compared to direct instillation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Benefits",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      has strong amnestic properties and is an effective anxiolytic in most children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3,11\">",
"       2,3,11",
"      </a>",
"      ]. The many potential routes of administration permit its use in children without vascular access. When used as the sole agent for sedation with proper dosing, respiratory depression is rare. Midazolam has a shorter duration of action than",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=see_link\">",
"       Flumazenil",
"      </a>",
"      is an effective reversal agent for the few patients who develop significant respiratory depression or apnea after sedation with midazolam. Flumazenil should",
"      <strong>",
"       not",
"      </strong>",
"      be used in patients with seizure disorders or those who receive benzodiazepines on a chronic basis because of the risk of precipitating seizures or withdrawal symptoms, respectively. The use of flumazenil to reverse adverse effects of benzodiazepines, including dosing and redosing recommendations is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"       \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      can cause respiratory depression and apnea, especially when combined with opioid medications such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Paradoxical reactions, including inconsolable crying, hyperactivity, and aggressive behavior may occur in approximately 1 to 3 percent of patients when midazolam is use as a single agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Both respiratory depression and paradoxical reactions can be reversed with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=see_link\">",
"       flumazenil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/39,42\">",
"       39,42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"       \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Midazolam is inferior as a sedative agent for computed tomography when compared to short-acting barbiturates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253072#H2253072\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Oral, rectal, or intranasal medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      has mild negative inotropic effects and should be used with caution in children with underlying myocardial depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2606931\">",
"    <span class=\"h2\">",
"     Short-acting barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbiturates induce sedation by inhibiting gamma-aminobutyric acid (GABA) receptors in the central nervous system.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     Pentobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/20/40262?source=see_link\">",
"     methohexital",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    are the barbiturates that are most commonly used to sedate children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Of these agents, pentobarbital has the best efficacy and fewest adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253072#H2253072\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Oral, rectal, or intranasal medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash; The initial intravenous dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      is 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum single dose 100 mg). This dose can be repeated every three to five minutes up to a maximum total dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum total dose 600 mg). Patients receiving concurrent barbiturate therapy (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) may require higher total doses up to 9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to achieve adequate sedation.",
"      <br/>",
"      <br/>",
"      The oral or rectal dose of pentobarbital varies by age. Children younger than four years of age can receive 3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by mouth (PO) or rectally (PR, maximum single dose 100 mg). Children four years of age and older are given 1.5 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO or PR (maximum single dose 100 mg).",
"      <br/>",
"      <br/>",
"      When used for pediatric procedural sedation,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/20/40262?source=see_link\">",
"       methohexital",
"      </a>",
"      is given IV or PR and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      is given PR. Dosing and other pharmacologic properties for these drugs are provided in the tables (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash; Respiratory depression or apnea occurs in approximately 2 to 11 percent of children who undergo sedation with short-acting barbiturates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/45-50\">",
"       45-50",
"      </a>",
"      ]. The risk of respiratory depression is lowest with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      and highest with rectal",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      . The potential for airway compromise increases when barbiturates are used in combination with other sedatives",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opioids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/44\">",
"       44",
"      </a>",
"      ]. Prolonged sleepiness is common after pentobarbital administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash; Use of barbiturates is contraindicated in patients with porphyria. Barbiturates have myocardial depressant effects and should be avoided in patients with hemodynamic instability or heart failure.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/20/40262?source=see_link\">",
"       Methohexital",
"      </a>",
"      can cause seizures in children with epilepsy and should be avoided in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7977221\">",
"    <span class=\"h2\">",
"     Chloral hydrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"     Chloral hydrate",
"    </a>",
"    was once the preferred sedative agent for diagnostic imaging in infants and children younger than three years of age and is efficacious for that purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. However, small trials and observational studies indicate that chloral hydrate is inferior to other sedation options because of its delayed onset of action, prolonged effect, and high frequency of adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In many regions, chloral hydrate is no longer available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253072#H2253072\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Oral, rectal, or intranasal medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       Chloral hydrate",
"      </a>",
"      may be given orally or rectally. The dose and other pharmacologic properties for chloral hydrate are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Adverse events",
"      </strong>",
"      &ndash; Airway obstruction, respiratory depression with intra- and postprocedural oxygen desaturation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      postprocedural bradycardia can occur, especially in term infants with younger chronological age, preterm infants with younger postconceptual age, and when higher doses are administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]. Prolonged observation up to 12 hours after",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      sedation may be necessary prior to safe discharge, especially in young infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/58\">",
"       58",
"      </a>",
"      ]. Procedural sedation protocols for monitoring should be followed for all patients receiving chloral hydrate because there is no consistent dose below which complications do not occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560720#H1560720\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindication and precautions",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       Chloral hydrate",
"      </a>",
"      is contraindicated in patients with renal, hepatic, or cardiovascular disease. Chloral hydrate is a mucosal irritant and should also not be given orally to patients with gastritis, esophagitis, or peptic ulcers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152491\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a dissociative sedative that provides effective sedation and analgesia for moderate to severely painful procedures.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    (N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ) is an inhaled anesthetic that provides mild analgesia and effective sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152498\">",
"    <span class=\"h2\">",
"     Ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a phencyclidine (PCP) derivative that acts as a dissociative sedative through binding of the N-methyl-D-aspartate (NMDA) receptor. There is no \"sedation continuum,\" and the effect is either present or absent. It produces a trance-like state and provides sedation, analgesia, amnesia, and immobilization, while usually preserving upper airway muscle tone, airway protective reflexes, and spontaneous breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3,16,59,60\">",
"     2,3,16,59,60",
"    </a>",
"    ]. Because of its rapid onset, relatively short duration of action and excellent sedative and analgesic properties, it often is used for brief, painful pediatric procedures, such as fracture reduction or laceration repair.",
"    <br/>",
"    <br/>",
"    Clinical practice guidelines for the use of ketamine have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. When used as part of a carefully developed protocol, ketamine can provide safe and effective sedation and analgesia.",
"   </p>",
"   <p>",
"    The clinical manifestations and management of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    toxicity (both iatrogenic and from illicit use) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40935?source=see_link\">",
"     \"Ketamine poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash; The initial intravenous (IV) dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      is 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      A repeat dose of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      may be administered after 10 minutes as needed. When given with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      , the IV ketamine dose is reduced to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      <br/>",
"      <br/>",
"      Ketamine may also be given intramuscularly (IM) in an initial dose of 4 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      with a repeated IM dose of 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      after 10 minutes as needed. However, IM administration is associated with more adverse effects and significantly longer recovery times. Thus, in children who are receiving procedural sedation with ketamine and have readily available vascular access, we recommend intravenous administration rather than intramuscular injection. Evidence supporting this recommendation is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In an observational study of 4252 children receiving IV or IM",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , of the 29 patients who experienced laryngospasm, 20 received ketamine by the IM route (OR 5.2; 95% CI 2.3-11.9; overall frequency of laryngospasm: 7 in 1000 sedations) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of 225 children who received either IV or IM",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      sedation for orthopedic reduction, IM injection was associated with significantly longer recovery times (total length of sedation: 129 versus 80 minutes in the IV ketamine group) and more vomiting (frequency of emesis: 26 versus 12 percent in the IV ketamine group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/64\">",
"       64",
"      </a>",
"      ]. However, no differences in adverse respiratory events between IV and IM administration were noted (8 versus 4 percent, respectively).",
"     </li>",
"     <li>",
"      The frequency of vomiting in 343 children between four months and five years of age undergoing sedation with IM",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      (dose: 4",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      was 28 to 31 percent and was not alleviated by pretreatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/47/759?source=see_link\">",
"       metoclopramide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/65\">",
"       65",
"      </a>",
"      ]. Normal diet was not tolerated for an average of seven to eight hours after sedation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash; Side effects of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      include increased vomiting, unpleasant hallucinations and rarely, apnea or laryngospasm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3,16\">",
"       2,3,16",
"      </a>",
"      ]. Hallucinations are most common in patients older than 15 years of age. Apnea and laryngospasm rarely occur and can generally be managed with positive pressure bag-mask ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/63\">",
"       63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We suggest that children receiving ketamine sedation receive premedication with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      or other serotonin receptor antagonists to reduce the frequency of vomiting. Ondansetron effectively reduces emesis after ketamine administration, especially in children younger than five years of age. As an example, in a clinical trial of 255 children receiving ketamine sedation, premedication with ondansetron reduced the absolute risk of vomiting in the emergency department from 13 to 5 percent (number needed to treat: 13) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/66\">",
"       66",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A variety of factors impact the frequency of adverse events. As an example, in a metaanalysis of 8282 pediatric ketamine sedations, the frequency of airway or respiratory adverse events was approximately 4 percent and was associated with patient age (younger than 2 years or 13 years of age and older), high initial intravenous dosing (&ge;2.5 mg per kilogram), total ketamine dose (&ge;5 mg per kilogram), and coadministration of an anticholinergic agent (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      ) or a benzodiazepine (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/67\">",
"       67",
"      </a>",
"      ]. In the same metaanalysis the frequency of emesis was 8 percent and was associated with patient age (highest at 12 years of age), high initial intravenous dosing (&ge;2.5 mg per kilogram), total ketamine dose (&ge;5 mg per kilogram), and intramuscular administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/68\">",
"       68",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In contrast, administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      prior to ketamine sedation is not associated with increased adverse events. As an example, in an observational study of 858 children undergoing sedation with ketamine that compared adverse events in cohorts of patients who did or did not receive morphine, patients who were pretreated with morphine did not have more adverse events (3 versus 5 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/69\">",
"       69",
"      </a>",
"      ]. Most children received morphine approximately 75 minutes before ketamine. Very few patients received morphine less than 30 minutes prior to ketamine sedation.",
"      <br/>",
"      <br/>",
"      Although administration of atropine or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      may reduce the amount of salivation, evidence suggests that these medications do not reduce laryngospasm and, thus, are not routinely necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/70-72\">",
"       70-72",
"      </a>",
"      ]. In one prospective study, only one of 947 children receiving ketamine without an anticholinergic agent experienced an adverse event that was felt to be due to hypersalivation (brief oxygen desaturation, estimated incidence 0.1 percent, 95% CI 0.0 to 0.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/71\">",
"       71",
"      </a>",
"      ]. In a systematic review of 8282 ketamine sedations performed in the emergency department and reported in 32 studies, children who received no anticholinergic agent had airway and respiratory adverse events in 3 percent of sedations compared with 3 and 6 percent of patients, who received atropine and glycopyrrolate respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/72\">",
"       72",
"      </a>",
"      ]. No differences in laryngospasm or apnea were found among the three groups.",
"      <br/>",
"      <br/>",
"      Similarly, although premedication with midazolam was once thought to minimize the side effects of ketamine sedation, especially vomiting and emergence phenomenon, it does not appear to be more efficacious than ondansetron for vomiting and has not been shown to impact the frequency of emergence phenomenon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/3\">",
"       3",
"      </a>",
"      ]. As an example, in one randomized trial, 266 children between the ages of five months to 16 years received ketamine sedation with or without midazolam [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/73\">",
"       73",
"      </a>",
"      ]. Sedation was equally effective, and emergence phenomena (hallucinations, nightmares, and severe agitation) were similar with the two regimens. Although midazolam premedication was associated with decreased vomiting (9.6 versus 19.4 percent) when compared to ketamine alone, it was also associated with an increased frequency of oxygen desaturation (7.3 versus 1.6 percent, respectively) especially in children younger than 10 years of age. Based on this evidence and our experience, we do not routinely use midazolam premedication when using ketamine for procedural sedation.",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      has numerous contraindications for procedural sedation (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      ).Ketamine should not be used in patients younger than 3 months of age, those with psychosis, or those with severe adverse reactions in the past. It is relatively contraindicated in other patients with the following conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/62\">",
"       62",
"      </a>",
"      ]::",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Airway instability",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Angina or heart failure",
"     </li>",
"     <li>",
"      Increased intracranial pressure caused by obstructive brain lesions that cause hydrocephalus",
"     </li>",
"     <li>",
"      Increased intraocular pressure (eg, glaucoma or eye injury) although a minimal increase in intraocular pressure of approximately 1 mmHg has been reported in a small series of children without eye injuries undergoing",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      sedation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Porphyria",
"     </li>",
"     <li>",
"      Thyroid disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152505\">",
"    <span class=\"h2\">",
"     Nitrous oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    (N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ) is an anesthetic gas that provides mild analgesia, sedation, amnesia, and anxiolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Spontaneous respirations, airway protective reflexes, and hemodynamic status are generally preserved at concentrations typically used for sedation and analgesia (50 to 70 percent N",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dosing and administration",
"      </strong>",
"      &ndash; Onset of sedation and recovery is very rapid with N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      . N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      is mixed with 30 to 50 percent oxygen and delivered through a demand-valve mask or continuous flow system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/78\">",
"       78",
"      </a>",
"      ]. Because the demand-valve mask requires cooperation and may be difficult to activate by smaller children, N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      is used primarily in patients older than four years of age. Continuous delivery systems (a mask strapped over the nose",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mouth) have been used in younger children with variable success [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]. This system is more frequently associated with emesis than the demand-valve technique [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Delivery systems include those that provide a fixed concentration of N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      with oxygen (typically 50 percent of each) or wall-mounted piped N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      and oxygen that permits increasing concentrations of N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      from 0 to 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. Essential safety features include the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/78,82\">",
"       78,82",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Automatic cut off of N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      if oxygen delivery fails",
"     </li>",
"     <li>",
"      Emergency oxygen override",
"     </li>",
"     <li>",
"      Maximum N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      delivery limit of 70 percent",
"     </li>",
"     <li>",
"      Color-coded tanks with different pin assemblies to attach to the delivery system so that practitioners cannot mistake an N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      tank for an oxygen tank",
"     </li>",
"     <li>",
"      Proportional delivery of N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      with oxygen",
"     </li>",
"     <li>",
"      Recovery of patients with a high concentration of oxygen (oxygen washout) to prevent diffusion hypoxia",
"     </li>",
"     <li>",
"      Adequate scavenger systems to prevent excessive occupational exposure to medical personnel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &ndash; N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      has an excellent safety profile for sedation in children with no major cardiopulmonary events (eg, apnea, significant hypoxia, bradycardia, or hypotension) reported in several large observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/78\">",
"       78",
"      </a>",
"      ]. Minor adverse effects include nausea, vomiting, and dysphoria. Of these, vomiting (up to 7 percent of patients) is most frequently reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/81\">",
"       81",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Deaths have been rarely associated with mechanical failure of the delivery system and inadvertent administration of 100 percent N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/78\">",
"       78",
"      </a>",
"      ]. Thus, clinicians must know how to test and use the equipment in use in their facility. In addition, equipment must be carefully maintained and periodically tested to ensure adequate safety.",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications and precautions",
"      </strong>",
"      &ndash; Contraindications to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      include nausea and vomiting, trapped gas within body cavities (eg, bowel obstruction, pneumothorax, middle ear infection), and pregnancy (increased risk of spontaneous abortion) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Furthermore, potentially pregnant medical personnel should not participate in N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Deeper sedation than anticipated can occur with prolonged inhalation and when N",
"      <sub>",
"       2",
"      </sub>",
"      O",
"      <sub>",
"       2",
"      </sub>",
"      is combined with opioids or benzodiazepines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/81\">",
"       81",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7977256\">",
"    <span class=\"h1\">",
"     ANALGESIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate analgesia can often lower the amount of sedative agent needed to provide adequate sedation and thus increase the safety of the procedure. The need for supplementary analgesia varies by the agents used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      has both sedative and analgesic properties and can thus be used alone to provide sedation for painful procedures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253108#H2253108\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      have limited analgesic properties that may be inadequate and warrant additional analgesic medications for moderately or severely painful procedures.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       Midazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      , do",
"      <strong>",
"       not",
"      </strong>",
"      have analgesic properties and need to be combined with other analgesic agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The analgesic medications most commonly combined with these sedatives during procedural sedation include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H223294\">",
"    <span class=\"h2\">",
"     Topical, local, and regional anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics can be delivered topically or by direct infiltration to diminish or abolish the pain associated with many procedures including intravenous cannula insertion, lumbar puncture, abscess drainage, or laceration repair. The topical anesthetic most frequently used for laceration repair is the combination of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    , epinephrine, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37648?source=see_link\">",
"     tetracaine",
"    </a>",
"    (LET), which becomes effective in approximately 30 minutes. For intact skin, EMLA, a eutectic mixture of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/43/34486?source=see_link\">",
"     lidocaine-prilocaine",
"    </a>",
"    in a cream base, and LMX 4, a nonprescription 4 percent liposomal lidocaine preparation, are also effective topical agents. They are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H2#H2\">",
"     \"Topical anesthetics in children\", section on 'LET'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H11#H11\">",
"     \"Topical anesthetics in children\", section on 'EMLA'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Local infiltration is typically performed using lidocaine. A variety of techniques may be used to decrease the pain of infiltration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link&amp;anchor=H540550#H540550\">",
"     \"Infiltration of local anesthetics\", section on 'Methods to decrease injection pain'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Regional anesthesia is also an effective means of procedural analgesia and includes techniques such as digital (",
"    <a class=\"graphic graphic_picture graphicRef50533 \" href=\"mobipreview.htm?0/12/192\">",
"     picture 1",
"    </a>",
"    ), dorsal penile (",
"    <a class=\"graphic graphic_figure graphicRef79052 \" href=\"mobipreview.htm?31/12/31938\">",
"     figure 1",
"    </a>",
"    ), facial nerve (",
"    <a class=\"graphic graphic_figure graphicRef64720 \" href=\"mobipreview.htm?35/20/36165\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77549 \" href=\"mobipreview.htm?43/17/44309\">",
"     figure 3",
"    </a>",
"    ) and Bier blocks. The procedures for performing these blocks are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/53/12122?source=see_link&amp;anchor=H8983021#H8983021\">",
"     \"Assessment and management of facial lacerations\", section on 'Facial nerve blocks'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33543?source=see_link&amp;anchor=H16#H16\">",
"     \"Paraphimosis reduction\", section on 'Local anesthesia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link&amp;anchor=H3483410#H3483410\">",
"     \"Overview of anesthesia and anesthetic choices\", section on 'Intravenous regional block'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    When local or regional anesthesia is used, sedation may also be provided to reduce pain and anxiety associated with performing local or regional anesthetic infiltration. Once successful pain control is achieved by local or regional anesthesia, requirements for additional procedural sedation (eg, additional doses or increased depth of sedation) are usually markedly reduced when compared to performing procedural sedation alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H223302\">",
"    <span class=\"h2\">",
"     Oral sucrose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the research that has evaluated oral sucrose for pain relief has occurred in preterm and term neonates. In this population, oral sucrose and other sweet-tasting liquids, such as glucose or saccharin, appear to be effective analgesics for minor procedures (eg, heel lancing). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35114?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and treatment of neonatal pain\", section on 'Oral sucrose'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The influence of factors, such as age, type of painful procedure, location in which the procedure is performed, and intercurrent illness on the analgesic effect of sucrose is uncertain. Nevertheless, sucrose appears to be safe and is easy to administer. A procedure for the administration of sucrose analgesia is described in the table (",
"    <a class=\"graphic graphic_table graphicRef76111 \" href=\"mobipreview.htm?10/55/11131\">",
"     table 4",
"    </a>",
"    ). The dosing of oral sucrose in term and preterm neonates is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35114?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and treatment of neonatal pain\", section on 'Dosing and administration'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In older infants, oral sucrose also appears effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of randomized controlled trials that studied the use of sucrose or glucose for control of pain prior to immunization in infants, 1 to 12 months, found significant reductions in the incidence and duration of crying [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in a pediatric emergency department described infants younger than 90 days who received sucrose prior to bladder catheterization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/84\">",
"       84",
"      </a>",
"      ]. The analgesic effect of sucrose was only significant among infants 30 days of age or younger.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H223310\">",
"    <span class=\"h2\">",
"     Fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is a synthetic opioid that has 75 to 125 times the potency of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    and provides analgesia for procedures with moderate to severe pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/44,85\">",
"     44,85",
"    </a>",
"    ]. Its rapid onset (within two to three minutes), relatively short duration of action (30 to 60 minutes), and lack of histamine release render it preferable for procedural sedation when compared to longer acting opioids, such as morphine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2,85\">",
"     2,85",
"    </a>",
"    ]. Morphine is an acceptable alternative if fentanyl is not available but has a longer onset and duration of action (20 minutes and four hours, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and management of pain in children\", section on 'Opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial dosing of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    may need to be adjusted for patients who have tolerance to opioids (eg, patients receiving chronic opioid analgesia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and management of pain in children\", section on 'Initial dosing'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Hypoxemia, respiratory depression, and apnea may occur when fentanyl is combined with other sedatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    ). Chest wall and glottic rigidity is a rare but life-threatening adverse effect of fentanyl [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. This muscle rigidity results in inability to ventilate the patient, even after endotracheal intubation. Although widely thought to primarily occur when large doses (eg, &gt;4",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    of fentanyl are given rapidly, perioperative chest wall rigidity has been reported in neonates, infants, and young children with single doses of fentanyl as low as 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    administration, neuromuscular blockade and endotracheal intubation may be needed to alleviate these symptoms.",
"    <br/>",
"    <br/>",
"    Although typically administered parenterally, fentanyl also can be effective when used intranasally or via nebulizer, as demonstrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, intranasal",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      (as compared with intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      ) provided effective analgesia for children with long bone fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small randomized trial, nebulized",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      was as effective as intravenous fentanyl for pain relief among children who presented to an emergency department with painful conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/29/31194/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573733\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The properties of commonly used agents for pediatric procedural sedation are discussed in this topic and summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ). Assessment, preparation, and proper performance of pediatric procedural sedation outside of the operating room, including selection of medications for pediatric procedural sedation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       Propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      , short-acting barbiturates (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/20/40262?source=see_link\">",
"       methohexital",
"      </a>",
"      ), and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      provide sedation but do",
"      <strong>",
"       not",
"      </strong>",
"      provide analgesia. Chloral hydrate is inferior to other sedation options because of its delayed onset of action, prolonged effect, and high frequency of adverse effects. (See",
"      <a class=\"local\" href=\"#H7977207\">",
"       'Sedative-hypnotic agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7977221\">",
"       'Chloral hydrate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      is a phencyclidine (PCP) derivative that acts as a dissociative sedative through binding of the N-methyl-D-aspartate (NMDA) receptor and is an effective single agent for sedation of children undergoing moderate to severely painful procedures. In children who are receiving procedural sedation with ketamine, intravenous administration is preferred. (See",
"      <a class=\"local\" href=\"#H2152498\">",
"       'Ketamine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253122#H2253122\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Moderately or severely painful'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Side effects of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      include increased vomiting, unpleasant hallucinations and rarely, apnea or laryngospasm. We suggest that children receiving ketamine sedation undergo premedication with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      to reduce the frequency of vomiting rather than no premedication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, premedication with anticholinergic agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      ) or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      does not significantly reduce adverse effects from ketamine sedation and is not routinely necessary. (See",
"      <a class=\"local\" href=\"#H2152498\">",
"       'Ketamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When providing sedation for painful procedures, addition of analgesia lowers the amount of sedative agent needed to provide adequate sedation and thus increases the safety of the procedure. The need for supplementary analgesia varies by the agents used (see",
"      <a class=\"local\" href=\"#H7977256\">",
"       'Analgesic agents'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      has both sedative and analgesic properties and can thus be used alone to provide sedation for painful procedures. (See",
"      <a class=\"local\" href=\"#H2152498\">",
"       'Ketamine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253108#H2253108\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      have limited analgesic properties that may be inadequate and warrant additional analgesic medications for moderately or severely painful procedures. (See",
"      <a class=\"local\" href=\"#H3220179\">",
"       'Dexmedetomidine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2152505\">",
"       'Nitrous oxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sedative-hypnotic agents, such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      do",
"      <strong>",
"       not",
"      </strong>",
"      have analgesic properties and need to be combined with other analgesic agents (eg, local or regional anesthesia or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) to provide effective sedation for painful procedures. (See",
"      <a class=\"local\" href=\"#H3220172\">",
"       'Propofol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2606114\">",
"       'Etomidate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7977214\">",
"       'Midazolam'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical, local, and regional anesthesia or systemic opioids (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) are the medications most commonly combined with sedative-hypnotic agents to provide procedural sedation for moderate to severely painful procedures. (See",
"      <a class=\"local\" href=\"#H7977256\">",
"       'Analgesic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral sucrose decreases the pain response to minor procedures (eg, heel lancing or immunization administration) in infants younger than one year of age and is suggested for such minimally painful procedures. (See",
"      <a class=\"local\" href=\"#H7977256\">",
"       'Analgesic agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35114?source=see_link&amp;anchor=H6#H6\">",
"       \"Prevention and treatment of neonatal pain\", section on 'Oral sucrose'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/1\">",
"      Kennedy RM, Luhmann JD. Pharmacological management of pain and anxiety during emergency procedures in children. Paediatr Drugs 2001; 3:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/2\">",
"      Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/3\">",
"      Sahyoun C, Krauss B. Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents in children. Curr Opin Pediatr 2012; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/4\">",
"      Martin TM, Nicolson SC, Bargas MS. Propofol anesthesia reduces emesis and airway obstruction in pediatric outpatients. Anesth Analg 1993; 76:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/5\">",
"      Pepperman ML, Macrae D. A comparison of propofol and other sedative use in paediatric intensive care in the United Kingdom. Paediatr Anaesth 1997; 7:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/6\">",
"      Vespasiano M, Finkelstein M, Kurachek S. Propofol sedation: intensivists' experience with 7304 cases in a children's hospital. Pediatrics 2007; 120:e1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/7\">",
"      Cravero JP, Blike GT, Beach M, et al. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics 2006; 118:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/8\">",
"      Cravero JP, Beach ML, Blike GT, et al. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg 2009; 108:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/9\">",
"      Mallory MD, Baxter AL, Yanosky DJ, et al. Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium. Ann Emerg Med 2011; 57:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/10\">",
"      Miner JR, Burton JH. Clinical practice advisory: Emergency department procedural sedation with propofol. Ann Emerg Med 2007; 50:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/11\">",
"      Kost S, Roy A. Procedural sedation and analgesia in the pediatric emergency department: a review of sedative pharmacology. Clin Pediatr Emerg Med 2010; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/12\">",
"      Heard C, Burrows F, Johnson K, et al. A comparison of dexmedetomidine-midazolam with propofol for maintenance of anesthesia in children undergoing magnetic resonance imaging. Anesth Analg 2008; 107:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/13\">",
"      Shah A, Mosdossy G, McLeod S, et al. A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children. Ann Emerg Med 2011; 57:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/14\">",
"      Srinivasan M, Turmelle M, Depalma LM, et al. Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions. J Pediatr 2012; 160:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/15\">",
"      Rothermel LK. Newer pharmacologic agents for procedural sedation of children in the emergency department-etomidate and propofol. Curr Opin Pediatr 2003; 15:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/16\">",
"      Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol for procedural sedation in children in the emergency department. Ann Emerg Med 2003; 42:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/17\">",
"      Cot&eacute; CJ, Notterman DA, Karl HW, et al. Adverse sedation events in pediatrics: a critical incident analysis of contributing factors. Pediatrics 2000; 105:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/18\">",
"      Green SM, Krauss B. Propofol in emergency medicine: pushing the sedation frontier. Ann Emerg Med 2003; 42:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/19\">",
"      Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother 2003; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/20\">",
"      Murphy A, Campbell DE, Baines D, Mehr S. Allergic reactions to propofol in egg-allergic children. Anesth Analg 2011; 113:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/21\">",
"      Mason KP, Prescilla R, Fontaine PJ, Zurakowski D. Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital. AJR Am J Roentgenol 2011; 196:W194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/22\">",
"      Mason KP, Zgleszewski SE, Prescilla R, et al. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth 2008; 18:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/23\">",
"      Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth 2010; 20:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/24\">",
"      Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth 2008; 18:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/25\">",
"      Cheung CW, Ng KF, Liu J, et al. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth 2011; 107:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/26\">",
"      Talon MD, Woodson LC, Sherwood ER, et al. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res 2009; 30:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/27\">",
"      Sakurai Y, Obata T, Odaka A, et al. Buccal administration of dexmedetomidine as a preanesthetic in children. J Anesth 2010; 24:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/28\">",
"      Karaaslan D, Peker TT, Alaca A, et al. Comparison of buccal and intramuscular dexmedetomidine premedication for arthroscopic knee surgery. J Clin Anesth 2006; 18:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/29\">",
"      Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders. Pediatr Neurol 2009; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/30\">",
"      Carroll CL, Krieger D, Campbell M, et al. Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit. J Hosp Med 2008; 3:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/31\">",
"      Hammer GB, Philip BM, Schroeder AR, et al. Prolonged infusion of dexmedetomidine for sedation following tracheal resection. Paediatr Anaesth 2005; 15:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/32\">",
"      Scheinin H, Aantaa R, Anttila M, et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology 1998; 89:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/33\">",
"      Berkenbosch JW, Tobias JD. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. Pediatr Crit Care Med 2003; 4:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/34\">",
"      Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg 2008; 106:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/35\">",
"      Mason KP, Zgleszewski S, Forman RE, et al. An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine. Anesth Analg 2009; 108:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/36\">",
"      Baxter AL, Mallory MD, Spandorfer PR, et al. Etomidate versus pentobarbital for computed tomography sedations: report from the Pediatric Sedation Research Consortium. Pediatr Emerg Care 2007; 23:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/37\">",
"      Lee-Jayaram JJ, Green A, Siembieda J, et al. Ketamine/midazolam versus etomidate/fentanyl: procedural sedation for pediatric orthopedic reductions. Pediatr Emerg Care 2010; 26:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/38\">",
"      Chiaretti A, Barone G, Rigante D, et al. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child 2011; 96:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/39\">",
"      Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila) 1997; 36:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/40\">",
"      Golparvar M, Saghaei M, Sajedi P, Razavi SS. Paradoxical reaction following intravenous midazolam premedication in pediatric patients - a randomized placebo controlled trial of ketamine for rapid tranquilization. Paediatr Anaesth 2004; 14:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/41\">",
"      Uldum B, Hallonsten AL, Poulsen S. Midazolam conscious sedation in a large Danish municipal dental service for children and adolescents. Int J Paediatr Dent 2008; 18:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/42\">",
"      Shannon M, Albers G, Burkhart K, et al. Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The Flumazenil Pediatric Study Group. J Pediatr 1997; 131:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/43\">",
"      Cook BA, Bass JW, Nomizu S, Alexander ME. Sedation of children for technical procedures: current standard of practice. Clin Pediatr (Phila) 1992; 31:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/44\">",
"      Cot&eacute; CJ. Sedation for the pediatric patient. A review. Pediatr Clin North Am 1994; 41:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/45\">",
"      Rooks VJ, Chung T, Connor L, et al. Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results. AJR Am J Roentgenol 2003; 180:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/46\">",
"      Mason KP, Zurakowski D, Connor L, et al. Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital. Radiology 2004; 233:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/47\">",
"      Mason KP, Sanborn P, Zurakowski D, et al. Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging. Radiology 2004; 230:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/48\">",
"      Malviya S, Voepel-Lewis T, Prochaska G, Tait AR. Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children. Pediatrics 2000; 105:E42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/49\">",
"      Pomeranz ES, Chudnofsky CR, Deegan TJ, et al. Rectal methohexital sedation for computed tomography imaging of stable pediatric emergency department patients. Pediatrics 2000; 105:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/50\">",
"      Glasier CM, Stark JE, Brown R, et al. Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies. AJNR Am J Neuroradiol 1995; 16:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/51\">",
"      Kienstra AJ, Ward MA, Sasan F, et al. Etomidate versus pentobarbital for sedation of children for head and neck CT imaging. Pediatr Emerg Care 2004; 20:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/52\">",
"      Pershad J, Palmisano P, Nichols M. Chloral hydrate: the good and the bad. Pediatr Emerg Care 1999; 15:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/53\">",
"      Macias CG, Chumpitazi CE. Sedation and anesthesia for CT: emerging issues for providing high-quality care. Pediatr Radiol 2011; 41 Suppl 2:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/54\">",
"      Rutman MS. Sedation for emergent diagnostic imaging studies in pediatric patients. Curr Opin Pediatr 2009; 21:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/55\">",
"      Olson DM, Sheehan MG, Thompson W, et al. Sedation of children for electroencephalograms. Pediatrics 2001; 108:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/56\">",
"      Greenberg SB, Faerber EN, Aspinall CL, Adams RC. High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age. AJR Am J Roentgenol 1993; 161:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/57\">",
"      Litman RS, Soin K, Salam A. Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications. Anesth Analg 2010; 110:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/58\">",
"      Cot&eacute; CJ. Safety after chloral hydrate sedation of former preterm and term infants for magnetic resonance imaging: are the data clear? Anesth Analg 2010; 110:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/59\">",
"      Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med 1998; 31:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/60\">",
"      Green SM, Rothrock SG, Harris T, et al. Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad Emerg Med 1998; 5:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/61\">",
"      Green SM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation in children. Ann Emerg Med 2004; 44:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/62\">",
"      Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011; 57:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/63\">",
"      Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. Pediatr Emerg Care 2009; 25:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/64\">",
"      Roback MG, Wathen JE, MacKenzie T, Bajaj L. A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Ann Emerg Med 2006; 48:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/65\">",
"      Lee JS, Jeon WC, Park EJ, et al. Adjunctive atropine versus metoclopramide: can we reduce ketamine-associated vomiting in young children? a prospective, randomized, open, controlled study. Acad Emerg Med 2012; 19:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/66\">",
"      Langston WT, Wathen JE, Roback MG, Bajaj L. Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. Ann Emerg Med 2008; 52:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/67\">",
"      Green SM, Roback MG, Krauss B, et al. Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. Ann Emerg Med 2009; 54:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/68\">",
"      Green SM, Roback MG, Krauss B, et al. Predictors of emesis and recovery agitation with emergency department ketamine sedation: an individual-patient data meta-analysis of 8,282 children. Ann Emerg Med 2009; 54:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/69\">",
"      Waterman GD Jr, Leder MS, Cohen DM. Adverse events in pediatric ketamine sedations with or without morphine pretreatment. Pediatr Emerg Care 2006; 22:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/70\">",
"      Heinz P, Geelhoed GC, Wee C, Pascoe EM. Is atropine needed with ketamine sedation? A prospective, randomised, double blind study. Emerg Med J 2006; 23:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/71\">",
"      Brown L, Christian-Kopp S, Sherwin TS, et al. Adjunctive atropine is unnecessary during ketamine sedation in children. Acad Emerg Med 2008; 15:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/72\">",
"      Green SM, Roback MG, Krauss B, Emergency Department Ketamine Meta-analysis Study Group. Anticholinergics and ketamine sedation in children: a secondary analysis of atropine versus glycopyrrolate. Acad Emerg Med 2010; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/73\">",
"      Wathen JE, Roback MG, Mackenzie T, Bothner JP. Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial. Ann Emerg Med 2000; 36:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/74\">",
"      Halstead SM, Deakyne SJ, Bajaj L, et al. The effect of ketamine on intraocular pressure in pediatric patients during procedural sedation. Acad Emerg Med 2012; 19:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/75\">",
"      Gamis AS, Knapp JF, Glenski JA. Nitrous oxide analgesia in a pediatric emergency department. Ann Emerg Med 1989; 18:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/76\">",
"      Hennrikus WL, Simpson RB, Klingelberger CE, Reis MT. Self-administered nitrous oxide analgesia for pediatric fracture reductions. J Pediatr Orthop 1994; 14:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/77\">",
"      Kanagasundaram SA, Lane LJ, Cavalletto BP, et al. Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures. Arch Dis Child 2001; 84:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/78\">",
"      Mace SE, Brown LA, Francis L, et al. Clinical policy: Critical issues in the sedation of pediatric patients in the emergency department. Ann Emerg Med 2008; 51:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/79\">",
"      Luhmann JD, Kennedy RM, Porter FL, et al. A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med 2001; 37:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/80\">",
"      Krauss B. Continuous-flow nitrous oxide: searching for the ideal procedural anxiolytic for toddlers. Ann Emerg Med 2001; 37:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/81\">",
"      Babl FE, Oakley E, Seaman C, et al. High-concentration nitrous oxide for procedural sedation in children: adverse events and depth of sedation. Pediatrics 2008; 121:e528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/82\">",
"      Holroyd I. Conscious sedation in pediatric dentistry. A short review of the current UK guidelines and the technique of inhalational sedation with nitrous oxide. Paediatr Anaesth 2008; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/83\">",
"      Harrison D, Stevens B, Bueno M, et al. Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review. Arch Dis Child 2010; 95:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/84\">",
"      Rogers AJ, Greenwald MH, Deguzman MA, et al. A randomized, controlled trial of sucrose analgesia in infants younger than 90 days of age who require bladder catheterization in the pediatric emergency department. Acad Emerg Med 2006; 13:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/85\">",
"      Joseph MH, Brill J, Zeltzer LK. Pediatric pain relief in trauma. Pediatr Rev 1999; 20:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/86\">",
"      Fahnenstich H, Steffan J, Kau N, Bartmann P. Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. Crit Care Med 2000; 28:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/87\">",
"      Dewhirst E, Naguib A, Tobias JD. Chest wall rigidity in two infants after low-dose fentanyl administration. Pediatr Emerg Care 2012; 28:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/88\">",
"      Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med 2007; 49:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/29/31194/abstract/89\">",
"      Miner JR, Kletti C, Herold M, et al. Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain. Acad Emerg Med 2007; 14:895.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82857 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31194=[""].join("\n");
var outline_f30_29_31194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H573733\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7977200\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7977207\">",
"      SEDATIVE-HYPNOTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3220172\">",
"      Propofol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3220179\">",
"      Dexmedetomidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2606114\">",
"      Etomidate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7977214\">",
"      Midazolam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2606931\">",
"      Short-acting barbiturates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7977221\">",
"      Chloral hydrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2152491\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2152498\">",
"      Ketamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2152505\">",
"      Nitrous oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7977256\">",
"      ANALGESIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H223294\">",
"      Topical, local, and regional anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H223302\">",
"      Oral sucrose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H223310\">",
"      Fentanyl",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H573733\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/82857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/82857|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/12/31938\" title=\"figure 1\">",
"      Dorsal penile block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/20/36165\" title=\"figure 2\">",
"      Mental nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/17/44309\" title=\"figure 3\">",
"      Infraorbital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/82857|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/12/192\" title=\"picture 1\">",
"      Digital block finger",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/82857|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/0/32782\" title=\"table 1\">",
"      Intravenous agents for pediatric procedural sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/28/31181\" title=\"table 2\">",
"      Agents other than intravenous for pediatric sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/5/9307\" title=\"table 3\">",
"      ASA physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/55/11131\" title=\"table 4\">",
"      Procedure for sucrose analgesia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/53/12122?source=related_link\">",
"      Assessment and management of facial lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33543?source=related_link\">",
"      Paraphimosis reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=related_link\">",
"      Preparation for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35114?source=related_link\">",
"      Prevention and treatment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=related_link\">",
"      Selection of medications for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_29_31195="Survival according to stage for thymic carcinoids in the SEER da";
var content_f30_29_31195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=20\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=20\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival according to stage for 160 thymic carcinoids reported to the SEER database",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        SEER stage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Survival rates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        One year",
"       </td>",
"       <td class=\"subtitle2\">",
"        Three year",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localized",
"       </td>",
"       <td>",
"        97 percent",
"       </td>",
"       <td>",
"        91 percent",
"       </td>",
"       <td>",
"        80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regional",
"       </td>",
"       <td>",
"        88 percent",
"       </td>",
"       <td>",
"        64 percent",
"       </td>",
"       <td>",
"        48 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distant",
"       </td>",
"       <td>",
"        81 percent",
"       </td>",
"       <td>",
"        48 percent",
"       </td>",
"       <td>",
"        31 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall",
"       </td>",
"       <td>",
"        89 percent",
"       </td>",
"       <td>",
"        66 percent",
"       </td>",
"       <td>",
"        53 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEER: Surveillance, Epidemiology and End Results database of the United States National Cancer Institute.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gaur P, Leary C, Yao JC. Thymic Neuroendocrine Tumors. A SEER database analysis of 160 patients. Ann Surg 2010; 251:1117. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31195=[""].join("\n");
var outline_f30_29_31195=null;
var title_f30_29_31196="Treatment of hypercalcemia";
var content_f30_29_31196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of hypercalcemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mode of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotonic saline hydration",
"       </td>",
"       <td>",
"        <p>",
"         Restoration of intravascular volume",
"        </p>",
"        Increases urinary calcium excretion",
"       </td>",
"       <td>",
"        Hours",
"       </td>",
"       <td>",
"        During infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcitonin",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits bone resorption via interference with osteoclast function",
"        </p>",
"        Promotes urinary calcium excretion",
"       </td>",
"       <td>",
"        4 to 6 hours",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bisphosphonates",
"       </td>",
"       <td>",
"        Inhibit bone resorption via interference with osteoclast recruitment and function",
"       </td>",
"       <td>",
"        24 to 72 hours",
"       </td>",
"       <td>",
"        2 to 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loop diuretics*",
"       </td>",
"       <td>",
"        Increase urinary calcium excretion via inhibition of calcium reabsorption in the loop of Henle",
"       </td>",
"       <td>",
"        Hours",
"       </td>",
"       <td>",
"        During therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoids",
"       </td>",
"       <td>",
"        <p>",
"         Decrease intestinal calcium absorption",
"        </p>",
"        Decrease 1,25-dihydroxyvitamin D production by activated mononuclear cells in patients with granulomatous diseases or lymphoma",
"       </td>",
"       <td>",
"        2 to 5 days",
"       </td>",
"       <td>",
"        Days to weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gallium nitrate",
"       </td>",
"       <td>",
"        Inhibits osteoclast-mediated bone resorption",
"       </td>",
"       <td>",
"        3 to 5 days",
"       </td>",
"       <td>",
"        2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcimimetics",
"       </td>",
"       <td>",
"        Calcium sensing receptor agonist, reduces PTH (parathyroid carcinoma, secondary hyperparathyroidism in CKD)",
"       </td>",
"       <td>",
"        2 to 3 days",
"       </td>",
"       <td>",
"        During therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dialysis",
"       </td>",
"       <td>",
"        Low or no calcium dialysate",
"       </td>",
"       <td>",
"        Hours",
"       </td>",
"       <td>",
"        During treatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Loop diuretics should not be used routinely. However, in patients with renal insufficiency or heart failure, judicious use of loop diuretics may be required to prevent fluid overload during saline hydration.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shane E, Dinaz I. Hypercalcemia: pathogenesis, clinical manifestations, differential diagnosis, and management. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (Sixth Edition). American Society of Bone and Mineral Research 2006; 179.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31196=[""].join("\n");
var outline_f30_29_31196=null;
var title_f30_29_31197="Initial management of patients with suspected aortic dissection";
var content_f30_29_31197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62587%7ECARD%2F60961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62587%7ECARD%2F60961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: Initial management of patients with suspected aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Detailed medical history and complete physical examination (whenever possible)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Intravenous line, blood sample (CK, troponin I, myoglobin, WBC, D-dimer, hematocrit, LDH)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. ECG: documentation of ischemia",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Heart rate and blood pressure (BP) monitoring",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Pain relief (morphine sulphate)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Reduction of systolic blood pressure using beta blockers (IV propranolol, metoprolol, esmolol, or labetalol)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Transfer to intensive care unit",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. In patients with severe hypertension additional vasodilator (IV sodium nitroprusside to titrate BP to 100-120 mmHg)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. In patients with obstructive pulmonary disease, blood pressure lowering with calcium channel blockers",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Imaging in patients with ECG signs of ischemia before thrombolysis if aortic pathology is suspected",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Chest x-ray",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: management of hemodynamically unstable patients with suspected aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Profound hemodynamic instability: intubation and ventilation.",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Transesophageal echocardiography as the sole diagnostic procedure; call surgeon.",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Surgery, based on findings of cardiac tamponade by transthoracic echocardiography.",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Pericardiocentesis (lowers intrapericardial pressure, may cause recurrent bleeding).",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31197=[""].join("\n");
var outline_f30_29_31197=null;
var title_f30_29_31198="Clinical protocol for fetal umbilical artery surveillance";
var content_f30_29_31198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Clinical guideline for the use of umbilical artery Doppler ultrasound in managing pregnancies complicated with fetal growth restriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 378px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UA: umbilical artery; NST: nonstress test; BPP: biophysical profile; AEDV: absent end-diastolic flow velocity in the umbilical artery; DI: Doppler index; REDV: reverse end-diastolic flow velocity in the umbilical artery.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dev Maulik, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31198=[""].join("\n");
var outline_f30_29_31198=null;
var title_f30_29_31199="Outcomes of ART by stage of procedure and maternal age";
var content_f30_29_31199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Outcomes of ART cycles using fresh nondonor eggs or embryos, by stage and age group, 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 455px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In 2006, a total of 99,199 cycles using fresh nondonor eggs or embryos were started:",
"    <br>",
"     &bull; 41,369 in women younger than 35",
"     <br>",
"      &bull; 23,376 in women 35-37",
"      <br>",
"       &bull; 19,775 in women 38-40",
"       <br>",
"        &bull; 9346 in women 41-42",
"        <br>",
"         &bull; 5333 in women older than 42",
"         <br>",
"          The above figure shows that a woman's chance of progressing from the beginning of ART to pregnancy and live birth (using her own eggs) decreases at every stage of ART as her age increases. As women get older, the likelihood of a successful response to ovarian stimulation and progression to egg retrieval decreases. As women get older, cycles that have progressed to egg retrieval are slightly less likely to reach transfer. The percentage of cycles that progress from transfer to pregnancy also decreases as women get older. As women get older, cycles that have progressed to pregnancy are less likely to result in a live birth because the risk for miscarriage is greater. Overall, 39 percent of cycles started in 2006 among women younger than 35 resulted in live births. This percentage decreased to 30 percent among women 35-37 years of age, 21 percent among women 38-40, 11 percent among women 41-42, and 4 percent among women older than 42. The proportion of cycles that resulted in singleton live births is even lower for each age group.",
"          <div class=\"footnotes\">",
"          </div>",
"          <div class=\"reference\">",
"           Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"          </div>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_29_31199=[""].join("\n");
var outline_f30_29_31199=null;
